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Technology, the subject of 
this issue, means change. And 
change is often good and bad—
more of the former, one hopes, 
than the latter.
Yale Medicine Magazine
(YMM) used to receive physical 
correspondence from readers, 
for example. That correspon-
dence would be printed on this 
page. Later, physical correspon-
dence was replaced by emails. 
More recently still, physical 
correspondence has almost 
entirely disappeared, which 
might be considered bad. That 
correspondence still occurs, 
though—in real time, via social 
media. It includes many more 
and varied voices than in the 
past, which is good ... but almost 
none of that dialogue is suitable 
for print (defi nitely bad).
Writers, thinkers, and scien-
tists have been considering the 
ethical ramifi cations of techno-
logical advances for years. At 
least as far back as Plato’s Ring of 
Gyges myth, thinkers were exper-
imenting with hypothetical sce-
narios, testing out likely human 
responses should some device 
change the terms on which one 
navigates society’s mores.
YMM’s “Letters to the Editor” 
page has become a disused 
venue for alumni, faculty, and 
students to share perspectives 
on past issues and articles at 
the same time that society has 
been wrestling with how to 
evaluate and process informa-
tion. Few fi elds have felt the 
impact of that crisis of confi -
dence in authority more acutely 
than science, which has been 
subjected to fallacious ques-
tions about the e  cacy of vac-
cinations, climate change, and 
even the signifi cance of cor-
relations between gun use and 
violence produced by guns.
As technology advances, it’s 
important to consider its rami-
fi cations, something at which 
doctors and scientists are 
adept. The medical profession 
is one of the few that abide 
by an ethical oath—to “do no 
harm.” It’s also important to 
communicate those changes, 
once weighed, to the lay audi-
ence. I’m proud to play a small 
ancillary role in facilitating that 
communication, both in print 
and online, via social media.
Adrian Bonenberger
Editor, Yale Medicine Magazine
note
As we transition to new mailing 
list software, we welcome 
any changes of name, address, 
or status at ymm@yale.edu.
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  Using technology to 
drive scientifi c advances
      have a long tradition of innovation in the 
technology sphere. Robert J. Alpern, MD, dean and Ensign Professor of Medicine, dis-
cusses the school’s current technological strengths and initiatives he believes will help 
continue carrying the school forward into the 21st century.
How is Yale School of Medicine taking advantage of advances in technology? Increasingly, advances in 
science are limited by advances in technology. In some fi elds, without certain devices, it’s impos-
sible to conduct clinical research. Top schools, including Yale, have to identify which cutting-edge 
technologies will give science and researchers the best opportunities, and invest in them. Advanced 
technologies are often very expensive in terms of money and expertise, so we’ve stepped forward to 
fund facilities that have the potential to be widely used by researchers. Cryo-electron microscopy 
is one recent example of this; no individual investigator could afford it, so the medical school and 
the provost’s offi  ce made a major investment in cryo-electron microscopy. Not just purchasing the 
equipment and fi nding a space for it, but also creating a core with technical expertise so that investi-
gators who need it for research but lack the mechanical know-how are able to use it.
How has that changed over your tenure? We’re able to do extraordinary things that just weren’t pos-
sible 20 years ago. A great example of this is DNA sequencing. When the instrumentation became 
available so that any university could perform state-of-the-art DNA or RNA sequencing, Yale made 
major investments so investigators could have access to this technology.  ose who have made use of 
this resource say it’s been a game-changer.
What has spurred those changes here at Yale? From the moment I stepped on campus, it became clear 
to me that one of the people really driving investment in technology to support research was Carolyn 
Slayman. Carolyn always believed in supporting this cause, and as the medical school’s fi nances have 
improved, it’s been easier to support more and different technological investments for faculty and 
students.  is type of thinking is now common in the top schools, but Carolyn was ahead of her time.
What does the school do if a device is di  cult to use or to maintain? It depends. In some cases, it’s just 
a question of giving researchers access and training and they’ll be able to use the device themselves. 
In the case of the cryo-electron microscope, the machine is so complex that many investigators just 
don’t know how to operate it correctly, and if they make an error, they’ll break it. Some investigators 
can use it properly and do, in their research. For those who need it, we make certain technical assis-
tance is available.  e point is to facilitate research, not bog scientists down with tasks outside their 
realm of expertise.
How does YSM di  er from competitor institutions? I tend to think about how we’re similar to other top 
institutions—which strengths are common to leading innovators. First of all, we want to develop technol-
ogy that’s useful to science and medicine. Second, if we can’t develop it ourselves, we want to be early 
adopters when others develop an exciting new device. DNA sequencing, again, was a place where we 
couldn’t develop or adopt at fi rst—if you weren’t part of the Human Genome Project you couldn’t build 
the DNA sequencers they were using. As soon as the DNA sequencers were developed commercially, we 





 One lab’s secret  
   to success
   meets every Friday in an office suite of 
the orthopaedics department. Medical students, several 
residents, and a few attending physicians sit around the 
table, eyes fixed on a monitor at the front of the small 
conference room. ey’re examining graphs and tables 
designed to explain the significance of medical data from 
thousands of patients across the country. 
Lab members comb through 
national (sometimes Yale-
specific) medical databases 
looking at outcomes of interest 
in the field of orthopaedics. By 
analyzing data from thousands 
of patients, they can gauge how 
well a treatment works; deter-
mine which conditions lead to 
surgical complications; and pro-
pose ways to optimize outcomes. 
To come up with research 
ideas, the group reads through 
published studies and asks how 
the so-called big data approach 
might find better answers to 
existing questions. “We define 
questions raised from the lit-
erature or from local discus-
sions and see what we have the 
tools to answer well. Often, we 
can resolve questions that have 
not been answered in the past, 
or use larger or more defined 
patient populations to address 
questions in novel ways,” said 
Jonathan N. Grauer, MD, interim 
chair and professor of orthopae-
dics and rehabilitation, and co-
director of the Spine Center at 
Yale New Haven Hospital.
When Grauer joined the Yale 
faculty in 2003, he worked in 
a lab conducting preclinical ani-
mal studies focused on bone for-
mation and spinal fusion. Over 
time his work evolved, and his 
research now relies on software 
and big data. 
Grauer’s conversion to this 
type of research came in 2012 
when a student approached him 
with an idea for a study. Rafael 
Buerba-Siller, MD ’14, MHS ’14, 
then a Yale medical student, 
asked Grauer whether he would 
be willing to help him apply 
big data research techniques 
to orthopaedics. Previously, 
Buerba-Siller had used such tools 
for studies in endocrine surgery. 
Grauer agreed to help: “And sure 
enough the study went great,” 
he said, opening “doors to novel 
approaches in orthopaedics and 
spine research.” 
e focus of Grauer’s research 
shifted from gathering data to 
posing questions, assessing data, 
and deriving clinically useful 
conclusions. By applying con-
temporary clinical questions to 
big data sets, Grauer’s Lab per-
formed more and more studies 
on varying topics in spine sur-
gery and orthopaedics. 
“I think [the lab] ranks pretty 
high in terms of productivity,” 
said Lee E. Rubin, MD, HS ’09, 
associate professor of ortho-
paedics and rehabilitation, who 
works with Grauer and helps 
guide the student members of the 
lab. He estimates that among the 
medical students who spend a full 
year of research in the Grauer Lab, 
“each will typically achieve 10 to 
15 completed projects that are 
presented or published.”
Pat Bovonratwet, MD ’19, 
joined the Grauer lab in 2016 
after his first year at Yale. “e 
upperclassmen had always 
told me, ‘Dr. Grauer’s the man 
to go to if you’re interested in 
orthopaedic research,’ ” he 
ymm.yale.edu4
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still remain involved, giving 
current members guidance, 
resources, or project ideas. 
is network is derived from 
Grauer’s dedication to research 
and his group. “He is a great 
mentor and supports his stu-
dents through medical school 




those interested in or 
connected to medicine
Gina Siddiqui, MD, had scarcely 
handled a screwdriver when she 
set foot last August in MakeHaven, 
the makerspace in downtown 
New Haven. “I didn’t know the 
difference between a screw and 
a bolt,” said Siddiqui, who’s in 
her third year of an emergency 
medicine residency at Yale New 
Haven Hospital. Over the course 
of the next 30 days, with training 
from MakeHaven staff, she mas-
tered everything from a hammer 
and chisel to a laser cutter as she 
built her husband a present for his 
birthday in early September—a 
large format view camera.
Working with maple and 
balsa wood, she crafted a camera 
with a holder for 5x7-inch film 
negatives, a tripod mount, and 
railings to support the bellows 
and lens she bought from a photo 
supply house. “I found it incred-
ibly invigorating,” Siddiqui said.
MakeHaven is one of about 
100 community-based maker-
spaces around the country—part 
of a growing movement that 
emerged in the early 2000s as 
inventors, tinkerers, hobbyists, 
and artisans banded together to 
ply their crafts and indulge their 
passion for creativity. e fruits 
of those labors ranged from 
inventions that would obtain 
patents and spawn companies to 
toys that glow in the dark. 
“ere is some fundamental 
need and satisfaction in making 
something,” said MakeHaven 
board member Joel Greenwood, 
PhD, director of neurotech-
nology in the Department of 
Neuroscience at the School 
of Medicine. “We are getting 
further and further away from 
making things,” he lamented.
His passion for building 
comes from his childhood on a 
farm an hour south of Seattle, 
where his parents lived off 
the land, growing vegetables, 
said. At the end of that sum-
mer, Bovonratwet published his 
first first-author paper. Since 
then, he has published a total of 
33 peer-reviewed papers from 
the Grauer Lab. Bovonratwet 
is listed as first author on 14 of 
those papers. 
is level of achievement is 
not unusual among the students 
in the Grauer Lab. “He’s very 
inclusive of medical students,” 
said Bovonratwet. “When I 
first joined, he told me, ‘I will 
always support you and your co-
students in leading the studies.’ ” 
Grauer gives the medical stu-
dents autonomy when it comes 
to research, guiding them at each 
step of the research process, and 
“helping them to develop their 
researcher skills,” Grauer said.
e lab is focused on mak-
ing a clinical difference. “We 
review these projects at every 
stage,” said Rubin. “Almost all 
of these publications find a way 
in [to journals] because it’s high-
quality research.” 
Part of the reason the lab can 
boast this high quality is that its 
members scrutinize the limita-
tions of their methods. “We’ve 
written many papers that call 
out the limitations of the type 
of research we do,” said Grauer. 
“In doing so, we become credible 
in the conclusions that we draw.”
According to Bovonratwet, 
aside from the research experi-
ence, lab members also ben-
efit from a dedicated mentor 
and a network of lab alumni. 
Bovonratwet noted that many of 
Grauer’s previous lab members 
Jonathan Grauer’s lab has 
an impressive record of 
publications. The secret is 
using big data to identify 
likely problem areas with 
orthopaedic surgery, as 
well as potential solutions. 
After his patients, Grauer’s 
students have been 
among the greatest ben-



















In 1965, a land mine 
landed Yale graduate 
George Cadwalader 
in a steamy tent of the 
3rd Surgical Mobile 
Hospital (MASH) in 
Vietnam. Little did he 
suspect that his sur-
geon, Captain Kristaps 
Keggi of the 173rd 
Airborne, was another 
son of Eli. Keggi, a YSM 
graduate, would save 
Cadwalder’s legs, and 
the two formed an 
unlikely friendship.
For more on their experi-
ence in Vietnam and 
after, visit ymm.yale.edu/
battlebuddies
to share it. It has broadened and 
gotten bigger.”
On a recent weekday, Nick 
McGhee was editing a pre-
sentation he and colleagues 
are making for a NASA design 
competition—a prototype of a 
human habitat for Mars. Upon 
their arrival on Mars, pioneers 
will need tools to turn Martian 
raw materials into a permanent 
home. “ e project we worked 
on is to develop the necessary 
technology,” said McGhee, who 
recently left his job as an aero-
space engineer to devote himself 
to the project. His project took 
third place and won $32,000.
Another member has used 
MakeHaven’s 3D printer to make 
prosthetic hands for children 
in the developing world. One 
member is working on a quad-
copter, which is a helicopter 
lifted and propelled by four 
rotors. Still another is using DIY 
instructions available online to 
make a book scanner.
Like others involved in 
MakeHaven, founding mem-
ber Ben Berkowitz, the CEO 
of SeeClickFix, grew up mak-
ing things—his father was a 
carpenter.  e past chair of 
MakeHaven’s board, he still 
and raising sheep and chick-
ens. Greenwood’s father was a 
home builder who had a two-
story woodshop on the prop-
erty. “I grew up building stuff,” 
Greenwood said. At Yale, he 
helps neuroscientists solve prob-
lems by teaching them to build 
the tools they’ll need, or direct-
ing them to people who can 
make equipment for them.
Like its peer spaces around 
the country, MakeHaven offers 
its 300 members a place to 
work, access to tools, and a 
like-minded community that 
provides feedback and shares 
ideas and techniques. While 
New Haven has other maker-
spaces, like Yale’s Center for 
Engineering Innovation and 
Design, MakeHaven is the only 
one that’s open to the commu-
nity at large. 
 e seeds for MakeHaven 
sprouted at a meetup in 2012. 
When critical mass grew to 
about 50 people, the partici-
pants chipped in to rent space 
on State Street and rummaged 
through their homes for tools. 
“Not all the tools were of the best 
quality,” said J.R. Logan, one of 
the founders and now execu-
tive director. “ ey were hand-
me-downs.” In March 2018, 
MakeHaven moved to a larger 
space—5,000 square feet in the 
basement of 770 Chapel Street, 
a building that also houses 
SeeClickFix. Tools are no longer 
basement relics: they include 
woodworking and metalwork-
ing equipment, an electronics 
workbench, 3D printers, sewing 
machines, printing presses, and 
a home brewing machine. In 
addition to space, tools, and 
training, MakeHaven offers 
talks, classes, and workshops.
As MakeHaven grew, members 
realized they could no longer rely 
on volunteers to run the place day 
to day. Logan, whose father was 
an inventor, was the fi rst full-
time employee. Kate Cebik works 
full time as operations manager. 
Lior Treshman is MakeHaven’s 
part-time “maker guru.” 
 e space sustains itself with 
dues ($50 per month, $35 for 
students) and grants, includ-
ing one from CTNext, which 
supports companies and entre-
preneurs with funding and 
mentorship programs. Members 
come with a variety of ambi-
tions. Some have patented their 
inventions, and some have given 
up their day jobs to pursue their 
projects. Others are hobby-
ists and tinkerers. “ ey fi nd 
joy in whatever is their area of 
technology,” said Logan. “ ey 


















prison sentence (think Dustin 
Hoffman’s character in Rain 
Man) to a fully treatable condi-
tion, driven by a wealth  
of research. 
“I’ve served as an editor for the 
Journal of ASD, and the number 
of submissions we get to publish 
papers has really taken off over the 
last 10 years,” said Volkmar. 
Even so, Volkmar said that 
there were gaps in research 
and treatment—specifically, 
studying two very promising 
fields, robotics and smartphone 
applications. Children on the 
autism spectrum have trouble 
with what psychologists call 
executive functions: monitor-
ing multiple stimuli and com-
pleting complex tasks. Social 
interactions are among the most 
complicated tasks humans per-
form many times over on a daily 
basis. Navigating those interac-
tions can quickly overwhelm 
children with ASD, which 
explains why they have dif-
ficulties interacting with oth-
ers as well as with the specific 
“I had some trouble as a kid—
acting out, throwing tantrums—
feeling misunderstood and 
apart. at’s an awful thing to 
go through when you’re young, 
and autism is the kind of disor-
der that, without therapy, can 
make alienation worse,” said 
Leaf. “Hearing Caio’s diagnosis, 
we wanted to give him the best 
treatment as soon as possible.”
“For the first 18 months, 
we’d been raising an infant, 
basically,” said Palmares. 
“Once we embraced what was 
happening, though, we started 
seeing improvements in Caio 
almost immediately.” 
ASD affects approximately 1 in 
59 children, and is nearly four 
times more likely to be diagnosed 
in boys than girls, according to 
the Centers for Disease Control 
and Prevention. While many 
children are diagnosed after age 4, 
there are reliable mechanisms for 
diagnosing children earlier. e 
earlier children are diagnosed, of 
course, the more effective treat-
ment can be. Caio’s diagnosis 
at the age of 3 put him in a good 
position to lead the kind of life 
available to most children, fully 
integrated into society.
Fred Volkmar, MD, the Irving 
B. Harris Professor in the Child 
Study Center and professor of 
psychology, is one of the people 
driving efforts to expand early 
diagnosis and treatment of 
children with ASD. He said that 
just in his lifetime he’s watched 
autism go from a once little-
understood diagnosis consid-
ered by many a kind of lifetime 
makes toys for his children 
and decorations for his office. 
“MakeHaven,” he said, “is a 
place to learn new skills and 
share ideas, to build businesses, 
and for anyone to achieve their 





autism one robot  
at a time
Parents can be resistant to hear-
ing that their child faces a chal-
lenging health diagnosis. But 
when omas Leaf and Emanuela 
Palmares learned that their 
son Caio has autism spectrum 
disorder (ASD), the diagnosis 
answered many questions with 
which they’d been grappling as 
parents and as individuals.
It wasn’t clear to them that 
Caio might be on the autism 
spectrum. Only after their 
insurance stopped covering 
hearing tests nearing Caio’s 
third birthday, did the two 
bring him into Yale’s Child 
Study Center to undergo evalua-
tion for a study. It turned out to 
be a wise decision.
“When they described Caio’s 
behavior in terms of autism, a lot 
of things clicked into place,” said 
Leaf. “His focus on a tree on the 
horizon and tuning the rest of the 
world out. His fixating on a soc-
cer line during a soccer game and 
ignoring the game around him. 
His difficulty discriminating fore-
ground from background noise.”
OPPOSITE New Haven’s 
MakeHaven is one of 
a network of makers 
communities across the 
country where innovation- 
minded citizens pool 
resources to buy and  
use machines few could 
aord on their own.  
Yale School of Medicine 
faculty and students  
have been known to use 
























YSM’s clinical research 
arm has benefi ted 





tion of systems can 
produce outsize 
operational results.
For more on YSM’s 
clinical research arm, 
visit ymm.yale.edu/
electronicrecords
challenges they face in profes-
sional environments. 
“Children on the autism spec-
trum get only about 10% of the 
social affective information in 
a scene, in large part because 
they’re looking at mouths, not 
eyes,” said Volkmar. “ e top half 
of the face is where the action 
is, socially speaking, in terms of 
nonverbal communication.”
Robots are interactive part-
ners with which children on the 
autism spectrum can feel com-
fortable because there is little or 
no nonverbal communication. 
 is simplicity can help children 
learn to express themselves 
without anxiety, which in turn 
can lead to better interactions 
with humans in the child’s life 
(adults, siblings, and friends). 
Brian Scassellati, PhD, the 
A. Bartlett Giamatti Professor 
of Computer Science and 
Mechanical Engineering and 
Materials Science, is develop-
ing robots designed specifi cally 
to help children on the autism 
spectrum improve social skills. 
He has worked with the Child 
Study Center and Volkmar to 
ensure that the robots are ide-
ally designed for children with 
ASD, down to a narrative for their 
arrival in the house and their 
imminent departure.  is nar-
rative has been tested in a recent 
study that was published in 
Science Robotics in August 2018.
“From the fi rst moment in 
the house, the robot tells a story 
about how it is a space explorer 
whose spaceship has broken 
down.  e child, in interacting 
with the robot, is helping it to 
perform tasks to get its spaceship 
working again. At the end of the 
study, the robot has fi xed its ship 
and can return to space, leaving 
the child’s home,” said Scassellati. 
“ is story helps the children 
build empathy at the same time 
that they’re building social skills, 
and makes the departure of the 
robot less disruptive.”
 us far, feedback has been 
extraordinarily and over-
whelmingly positive, accord-
ing to Scassellati. “All of the 
children in the study made 
signifi cant gains in their social 
skills, and the robots were 
very well received.  e parents 
don’t want the robots to leave; 
even more so than the children, 
even.” He said that after the 
robots left, some of the children 
lost the gains they had made, 
but that in and of itself isn’t 
exceptional. “We didn’t expect 
the robots to create permanent 
changes after just a month. Our 
best therapies don’t work that 
quickly,” he said.
Apps are another way to 
help children with ASD. David 
Grodberg, MD, FW ’99, assis-
tant professor of psychiatry and 
medical director of the Child 
Study Center’s Outpatient Clinic, 
has been developing an applica-
tion to help parents learn to use 
the same behavioral interven-
tions with their children that 
are used by experts. “Much of 
the important work that’s done 
by professionals in a clinical set-
ting can—must, really—be aug-
mented by engaging the parents 
and other caregivers,” he said. 
Giving them tools to guide their 
treatment plans along carefully 
prescribed lines and with feed-
back from clinicians is key, he 
said, to maximizing the benefi t 
to affected children.
Palmares, who has since 
remarried, noted that having a 
child with ASD requires great 
efforts as a parent, but also that 
the process has been personally 
rewarding. “Caio has made me a 
better mother and a better wife,” 
she said. She and Leaf divorced 
not long after Caio’s diagnosis, 
for reasons unrelated to his con-
dition, and “co-parenting him 
has allowed both of us to forgive 
each other and have a healthy, 
respectful relationship. We have 
to, for Caio’s sake.”
Leaf agreed. “I think 
Emanuela and I both see raising 
Caio as a call to make ourselves 
better people. I remember my 
childhood, growing up as an 
outsider, not really feeling at 
home until I went to Hopkins 
[a private school in New Haven]. 
Caio’s never going to feel like 
he’s a bad kid, like he’s weird or 
unaccepted. He is who he is.”
Caio has become adept at using 
educational apps, and has his own 
programmable robot that he loves 
playing with. He’s even mastered 
a form of programming to get 
the robot to perform different 
tasks. Increasingly, what could 
have been a debilitating condition 
is for Caio and children like 





One in three American children will expe-
rience a clinically significant anxiety dis-
order before adulthood. Eli Lebowitz, PhD, 
associate professor in the Child Study 
Center, recently conducted a study that 
concluded that counseling the parents 
of anxious children can be as eective 
in treating common anxiety disorders 
as cognitive behavioral therapy for the 
children. Lebowitz’s program is called 
SPACE (Supportive Parenting for Anxious 
Childhood Emotions). Parents in the 
SPACE program are counseled to be less 
accommodating; that is, to reduce the 
number of changes they make in their own 
behavior to lower the child’s distress.
A project involving research-
ers at Yale and in China 
gauges the potential for 
smartphones to improve 
heart health in a country with 
high rates of heart disease. 
Patients in dierent regions 
across China diagnosed with 
chronic heart conditions 
received supportive text mes-
sages as well as texts oering 
guidance on daily activities to 
support specific health goals. 
While the messages did not 
result in significant changes 
to the participants’ blood 
pressure, most of the subjects 
liked them and wanted to con-
tinue to receive informational 
and motivational support 
after the study ended. 
Clusters of people with a his-
tory of opioid use who present 
without the ability to form 
new memories—a kind of brain 
damage—may oer a clue to 
amnesia, inflammation, and the 
process of memory loss. Adam 
Jasne, MD, assistant professor 
of neurology, observed swelling 
in the cerebellum and hippo-
campus (a part of the brain 
involved in memory formation) 
in six drug-overdose patients 
suering from amnesia. 
Sometimes the brain swelling  
is fatal, and even when it isn’t, 
the patient can have perma-
nent memory impairment 
along with such physical prob-
lems as movement abnormal-
ities and seizures.
Together with researchers at 
University College London, sci-
entists at Yale looked closely 
at how cells behave when 
repairing skin tissue. By using 
traction force microscopy, the 
researchers identified two 
mechanisms by which muscle 
proteins are brought to the 
edge of a wound to close it: 
using protein actin projec-
tions called lamellipodia at the 
leading edge of a cell to move 
the entire cell, or by forming 
a “purse string” bundle of cells 
across the leading edge of the 
wound. Understanding these 
coordinated cellular behaviors 
will help researchers develop 




COUNSELING PARENTS TO 
HELP TREAT KIDS’ ANXIETY
TEXTING FOR A 
HEALTHY HEART
MEMORY LOSS  
IN OPIOID USE
The kidney, according to the 
Centers for Disease Control 
and Prevention, is among the six 
most commonly transplanted 
organs in the United States. 
Recent research indicates, 
however, that Black patients 
encounter significantly more 
diculty in receiving a kidney 
for transplantation. The reasons 
for the disparity are not com-
pletely clear, but one major fac-
tor is that Black patients are less 
likely to be moved from inactive 
to active status on the trans-
plant waiting list after initial list-
ing. Researchers suggest that 
better coordination between 
kidney dialysis units and trans-
plant centers would help solve 
the problem. 
RACIAL DISPARITIES IN 
KIDNEY TRANSPLANT
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AS DOCTOR S AND R ESEARC HER S become increasingly specialized in 
their fields, so too do the tools and technology they use to diagnose and treat pa-
tients as well as conduct research. These tools are themselves the product of ex-
pertise, and one of the strengths of Yale School of Medicine (YSM) is the wealth 
of informal and formal collaborations between clinicians and inventors. 
This issue looks at some of those technological collaborations among doc-
tors, scientists, and engineers that have led to breakthroughs, as well as innova-
tions that are ongoing or imminent. Abby Roth’s “Honing clinical skills with ultra-
sound” considers how advances in machines, as well as such pedagogical tools 
as smart tablets, can help students hone their skills before setting foot in the 
clinic. Ken Byron writes about an undergraduate class in biomedical engineering 
co-taught by assistant professor of surgery Daniel Wiznia, MD, and Steven Tom-
masini, PhD, which focuses on engineering solutions to real-world orthopaedics 
problems. And former Yale Medicine Magazine editor John Curtis has compiled 
a timeline of medical innovation that sets some of Yale’s and YSM’s more notable 
achievements in historical context.
There’s a lot more—the synthesis between imaging and 3D printing could 
take up a whole issue by itself, and there are several stories in these pages that 
dive into advances in that field.
It’s an exciting time to be working on technological solutions to medical 
problems, and YSM is proud to oer workshops, laboratories, and funding to 
people who contribute to that work. 
The new machinery of medicine 12
Building lung capacity, lung-first 18
A perfect day for a zebrafish 20
Where scientists and entrepreneurs mingle 24
Honing clinical skills with ultrasound 27
Engineering innovation 31
When skin-deep is all you need 34
Scratching the surface: Metallic glass implants 36
Technology: A tool for treatment
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Just four months after Elsa Violante was born, she 
began to have seizures. e spasms lasted from 30 sec-
onds to four minutes, and they came every 15 minutes 
to half an hour. Her parents, Alexis and Christiane 
Violante, rushed her to her pediatrician near their 
home in suburban Toronto. He sent them to the emer-
gency department of a downtown hospital.
e diagnosis was early infantile epileptic encepha-
lopathy, a rare and serious condition that can have 
debilitating lifelong effects. “After they told us what it 
really was, it became terrifying,” says Alexis.
Physicians at the Hospital for Sick Children 
(SickKids) in Toronto tried one treatment after another 
to address Elsa’s seizures, but they couldn’t identify 
the underlying cause. So they sent the  
family’s blood tests to Yale Medicine’s Pediatric 
Genomics Discovery Program (PGDP). Using gene 
sequencing machines, high-performance computers, 
and CRISPR-Cas9 genome editing technologies,  
the PGDP team discovered that a rare variant of the 
gene NEUROD2 on chromosome 17 is responsible  
for Elsa’s condition.
Ultimately, a high-fat low-carbohydrate diet 
addressed Elsa’s seizures, but physicians can’t repair 
her damaged nervous system. At age 5, she is unable 
to walk or even sit up, and she has limited control of 
her arms and hands. Yet her parents hope that medical 
science will produce advances that will make Elsa’s life 
better—and that the discovery of the NEUROD2 variant 
will help other kids and families. 
Elsa’s story illustrates a powerful melding of tech-
nologies that’s helping to solve the mysteries of life 
and to usher in the era of precision medicine. Gene 
sequencing, computer data analysis, and the simula-
tion of scenarios using experimental genome editing 
techniques enable researchers to identify and under-
stand the differences among people on the genetic 
level. As a result, we can better diagnose diseases and 
choose—or design—treatments tailored to help indi-
vidual patients. “From the standpoint of medicine and 
health, this can be transformative—and in ways that 
we can’t even appreciate now,” says Saquib Lakhani, 
MD, assistant professor of pediatrics and clinical direc-
tor of the PGDP program.
Yet this combination of tools is just one of many 
applications of technology to medicine that are chang-
ing the ways medical researchers do their work and 
physicians treat patients. For decades, technology has 
played a critical role in medicine. From the iron lung 
in 1929 through the cardiac pacemaker, the artificial 
heart, and robotic surgery in more recent times, engi-
neers and medical scientists have long collaborated to 
produce innovations at the intersections of their fields. 
Yale faculty members have been in the vanguard. 
Scientists and clinicians here were pioneers in the 
use of magnetic resonance imaging (MRI) machines. 
William V. Tamborlane, MD, FW ’77, professor of 
pediatrics, and Robert S. Sherwin, MD, FW ’74, the 
C.N.H. Long Professor Emeritus of Internal Medicine 
(Endocrinology), developed the insulin infusion pump 
For patients suering from genetic disorders or diseases that 
may be cured by a combination of three new technologies, 
the clinical applications can’t come quickly enough.
the new machinery 
of medicine
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for people with diabetes. Stuart Weinzimer, MD, 
professor of pediatrics, led a team that produced an 
artificial pancreas. And Jonathan Rothberg, PhD ’91, 
professor (adjunct) of genetics, developed high-speed 
“Next-Gen” DNA sequencing.
Perhaps the most important advance in computer-
related genetics research at Yale came in 2009, when 
a research team led by Richard Lifton, MD, PhD, who 
was then chair of the Department of Genetics and is 
now president of Rockefeller University, used new 
technologies to discover the genes and biochemical 
mechanisms that cause hypertension. Lifton’s team 
developed a technique for performing whole-exome 
sequencing, enabling researchers to examine the 
protein-coding region of the human genome (about 
1% of the whole) at much lower cost than sequencing 
the full genome.
Medical technology innovation accelerated after 
the Institute of Medicine in 1999 released a report 
titled To Err is Human: Building a Safer Health 
System, according to Peter Schulam, MD, PhD, chair 
of the Department of Urology and chief innovation 
and transformation officer for the Yale New Haven 
Health System. e report called for technology-based 
advances aimed at improving the quality of health care. 
Since then, a host of new devices and computer-based 
tools have been introduced that enable physicians to 
do their jobs better. “Technology has the potential to 
minimize human variability and improve patient out-
comes,” Schulam says.
Yale is newly committed to playing an even more 
prominent role in bringing technology to bear on 
humanity’s most critical problems—with medicine 
as a top priority. e University Science Strategy 
Committee (USSC) last year unveiled a plan to accel-
erate discoveries, often through multidisciplinary 
collaborations. Focus areas in medicine include 
neuroscience, inflammation science, conquering can-
cer, regenerative medicine, and precision medicine. 
“A large fraction of the modern frontiers of scientific 
and medicine research is interdisciplinary,” says Peter 
Schiffer, PhD, vice provost for research. “You’ve got 
data people working with fundamental scientists, with 
clinicians, and with the engineers designing devices.” 
Because data analysis plays an important role in 
most of these cross-disciplinary endeavors, Schiffer 
is working with leaders of schools and departments 
to provide researchers and students with the com-
putational resources they need. Until recently, most 
faculty members and programs at Yale purchased 
and operated their own research computers. But in 
2015, the university opened Yale Center for Research 
Computing (YCRC), which has five clusters of comput-
ers made available to researchers as shared resources.
e YCRC’s computers are housed in a nondescript 
former manufacturing building on Yale West Campus. 
One of the clusters is dedicated to genetic research. 
Named Ruddle (for Francis Ruddle, PhD, a Yale pio-
neer in genetic engineering), the cluster is made up of 
two parallel rows of metal racks containing comput-
ers, storage devices, and the networking equipment to 
allow them to communicate. Between the racks, it’s 
hot and noisy.
Ruddle has roughly the same computational power 
as you would get by stringing together 2,000 or so 
high-end laptop computers. In addition, it possesses 
three petabytes (three quadrillion bytes) of digital 
storage. at’s a lot. If you were to fill Ruddle’s stor-
age devices with MP3-encoded songs, you could play 
music for 6,000 years.
e reason Ruddle needs so much computing power 
sits directly across the street from the data center— 
Yale Center for Genome Analysis (YCGA). ere,  
scientists and technicians use million-dollar gene-
sequencing machines and other tools to help faculty 
members and students perform their research. e 
gene sequencing takes place at YCGA, while the analy-
sis of the results is done with Ruddle. In some cases, 
diseases are caused by variants in multiple genes, 
so analysis of the interplay among the genes requires 
a large amount of computing power.
Saquib Lakhani, 
Clinical Director 










e scale of this type of computation is tremen-
dous. Each individual human genome contains about 
3 billion DNA base pairs. It took more than a decade 
and about $2.7 billion to sequence the first human 
genome—a feat completed in 2003. Now, because of 
advances in gene-sequencing techniques and high-
performance computing, technicians can sequence and 
analyze an entire genome in a couple of days for about 
$1,000. Sequencing of the whole exome, which is the 
protein coding subset of the genome in which most 
disease-causing variants occur, costs about $200 and 
can be completed in a few hours.
e PGDP research team uses whole-exome sequenc-
ing to make discoveries in such cases as Elsa Violante’s. 
Using techniques initially developed by Lifton, a 
family’s blood samples are submitted to the YCGA or 
another facility like it for sequencing. Next, the com-
puters are used to identify potential variants of interest. 
e research team looks at these results, as well as the 
specific problems a child has, to find the very best can-
didates for testing. In the case of Elsa and another child 
with similar seizures, variants in the NEUROD2 gene 
became the focus. 
e PGDP scientists used CRISPR-Cas9 genome edit-
ing in frog eggs to explore further. ey introduced 
CRISPR-Cas9 molecules into the eggs through a tiny 
needle. e molecules worked together to target and 
eliminate the NEUROD2 sequence. ese eggs were 
then incubated and tadpoles emerged over the next few 
days. Researchers observed the tadpoles’ behavior as 
they developed, and they noticed convulsions. Bolstered 
with other evidence, they concluded that NEUROD2 
variants were the cause of the seizures in both children. 
“We hope this discovery helps other children with 
infant-onset epilepsy caused by NEUROD2 variants to be 
identified sooner, to hopefully have appropriate seizure 
treatments sooner,” says Lauren Jeffries, DO, the clinical 
genetics coordinator for PGDP. “Having a specific genetic 
diagnosis can help doctors and families have better 
understanding of treatments, outcomes, and predictions.”
While giving a tour of the YCGA lab, its director, 
Shrikant Mane, PhD, professor of genetics, proudly 
shows off the latest gene sequencing machines, which 
are the size of small refrigerators. en, with a twinkle 
in his eye, he removes a device the size of a smart-
phone from a box and waves it in the air like a magic 
Medical devices and technology 
across the years
As long as humans have had the ability to craft tools, they’ve 
been using them to solve medical problems. Over time,  
the tools have become increasingly complex and sophisticated. 
By John Curtis
The new machinery of medicine
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wand. “e latest technology that’s on the market—
this is a sequencing machine,” he says. 
e device he’s holding is a portable DNA sequencer 
developed by Oxford Nanopore Technologies, which 
is designed to enable physicians and researchers to 
sequence small fragments of DNA or RNA. In one sce-
nario, health workers in Africa could use the device 
to test patients in remote villages for Ebola fever. e 
sequencer costs just $1,000. “You can carry this in your 
backpack. All you need is the human samples and a 
laptop. is is the future,” Mane says.
While miniaturization in electronics will make such 
devices ever smaller and cheaper, the data sets that 
scientists and clinicians work with are getting ever 
larger. But that’s a good thing. By combining detailed 
genetic information from hundreds of thousands (and 
soon millions) of people with data from electronic 
medical records and information from research data-
bases, researchers and clinicians can take into account 
a wealth of information when they make decisions that 
guide research or patient care.
A new initiative at Yale is aimed at rapidly collect-
ing genetic data that can be used for research and care. 
e Generations Project, launched earlier this year by 
Yale Medicine, Yale New Haven Health, and other part-
ners, aims to create a DNA biobank with genetic data 
from more than 100,000 people over the next three 
to five years. eir genetic data will be linked to their 
electronic health records. Participants will have their 
genes sequenced and screened for early detection of 
diseases and for variants that pose risks. In addition, 
the data will be available to researchers performing 
broad-based studies.
Electronic health records are essential. Without 
the ability to examine an individual patient’s biology 
closely and compare what’s happening with that per-
son to what has happened to many others, it’s difficult 
to truly understand diseases, to treat patients opti-
mally, and to measure treatment outcomes.
For Harlan Krumholz, MD, the Harold H. Hines, 
Jr. Professor of Medicine (Cardiology) and director of 
Yale’s Center for Outcomes Research and Evaluation, 
all of this new data and computing power is a bonanza. 
“In the past, we looked at large averages and said the 
results applied to everybody,” he says. “Now, with the 
combination of all that data and remarkable computing 
6000 BCE  
During the Upper 
Paleolithic and Me-
solithic times, knives, 
saws, and drills made 
of stones such as  




The world’s oldest 
prosthetic devices 
are toes for amputees, 
made in ancient Egypt 
of wood and leather.
300-500 CE  
The Greeks and  
Romans set the 
patterns of modern 
surgical instruments 
with new tools, often 
made of bronze. 
1268  
It is hard to credit 
any single scientist 
with the invention 
of spectacles, but 
Roger Bacon’s stud-
ies of optics lead to 
development of this 
visual breakthrough. 
Scholars and monks 
had used an early pro-
totype held before 





maker, is credited 
with the invention 
of the compound 
microscope, although 
controversy remains 
regarding this claim. 
In 1734, Yale becomes 
the first college in 
America to obtain 
one. More than 50 
years later, Yale lists 
a microscope as one 





enheit, a Dutch- 
German-Polish inven-
tor and instrument 
maker, invents the 
mercury-in-glass 
thermometer. The 
basic principles of 
the thermometer had 
been known to Greek 
philosophers 2,000 
years earlier, while 
Galileo had invented 
a device to measure 
temperature called a 
thermoscope in the 
late 1603.
1816  
A French physician 




tube—to cover the em-
barrassment of press-
ing his ear to the chest 
of a female patient.
1851 
Hermann von 
Helmholtz, a German 
physicist, invents the 
ophthalmoscope to 
examine the retina 
and other parts of the 
interior of the eye.
1853 
Independently of 
each other, Charles 
Gabriel Pravaz, MD, a 
French surgeon, and 
Alexander Wood, MD, 
a Scottish physician, 
develop the hypo-
dermic syringe. The 
general principle of 
injection had been 
known for at least 
1800 years—Greek 
and Roman physicians 
had used thin, hollow 
tools known as piston 
syringes to inject 
fluids into the body. 
1895  
Wilhelm Conrad 
Roentgen, PhD, a 
German engineer and 
physicist, discovers 
X-rays. The first X-ray 
images in the United 
States were pub-
lished a month later 
by Yale professor  
Arthur W. Wright, 
PhD and the first clini-
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power at our fingertips, we can make inferences that 
are much more focused on individuals.”
Yale New Haven Health is in the process of build-
ing a computer system designed to fulfill the promise 
of precision medicine. It’s bringing data from many of 
its existing computing systems into a centralized “data 
lake” where information can be readily accessed and 
analyzed. is huge collection of data includes not just 
basic electronic health records but also genetic data; 
test results from imaging systems and the pathology 
department; and real-time data collected from moni-
toring devices in the intensive care unit. 
Krumholz predicts that medicine will be trans-
formed by data within a decade. “We will move from 
a place where research and clinical care are separate 
domains to one where we learn from every interac-
tion with a patient—it’s built into the system,” he says. 
“With every click, the system gets smarter and more 
customized. We leverage everything that everyone  
has done and is doing.”
It’s not just the amount of data that matters; 
it’s also how quickly you can analyze them. High-
performance computers are essential here. Krumholz 
can imagine a time in the not-too-distant future when 
a clinician who is meeting with a patient with complex 
health issues will be able to query a computer and get 
advice from an artificial intelligence program about a 
diagnosis or a personalized treatment plan on the spot—
before the patient leaves the office.
In research settings, this kind of real-time response 
is already possible. Nicholas Turk-Browne, PhD ’09, a 
professor of psychology and neuroscience, uses high-
performance computing along with functional magnetic 
resonance imaging (fMRI) to better understand how 
the brain works. Measuring brain activity by detecting 
changes in blood flow, it correlates activities in vari-
ous segments of a person’s brain with different kinds 
of thinking and emotions. Today, with a collaborative 
research team, Turk-Browne is using the system to 
train people diagnosed with major depressive disorder 
to avoid negative thoughts and feelings. “If we can get 
people to change what they’re focusing on, we can avoid 
some of the negative symptoms,” he says.
With all of this mingling of medicine and comput-
ers, medical researchers and even clinicians are being 
asked to develop computer science expertise. Yale’s 
1903  
Willem Einthoven, 
MD, a Dutch physi-
cian, refines the 
electrocardiogram 
developed by a Brit-
ish physiologist and 
devises an instrument 
to record the heart’s 
electrical impulses. 
1924  
Hans Berger, MD, a 
German physiologist 
and psychiatrist, ex-
pands on Einthoven’s 
work and develops a 
method for recording 
human brain waves 




An American engineer, 
Philip Drinker, creates 
the iron lung, a device 
that breathes for 
polio patients who 




engineers Max Knoll 
and Ernst Ruska de-
sign the first electron 
microscope, which 
magnifies tiny intra-
cellular structures far 
beyond the capacity 
of light microscopes. 
George E. Palade and 
colleagues found the 
Section of Cell Biolo-
gy at Yale in the 1970s, 
where they merge 
electron microscopy 
with biochemistry to 
lay the foundation of 
modern cell biology. 
Palade wins the Nobel 
Prize in Medicine or 
Physiology in 1964, a 
year after his arrival 
at Yale.
1937 
The Soviet scientist 
Vladimir Demik-
hov makes the first 
artificial heart. It is 
transplanted into a 
dog, which survives 
for two hours after 
the surgery.
1943 
Willem J. Kol, MD, 
PhD, a Dutch physi-
cian invents the ar-
tificial kidney, which 
evolved into modern 
dialysis machines.
1947 
John Bardeen, Walter 
Brattain, and William 
Shockley invent a 
semiconductor device 
called the transis-
tor at Bell Labs. It 
becomes a key piece 
of virtually every elec-
tronic device, leading 
to the development of 




valves, glass tubing, 
and a pump from an 
Erector Set, a Yale 
surgeon, William 
W.L. Glenn, MD, and a 
medical student, Wil-
liam Sewell, create an 
external heart pump 
for $24.80. Yale used 
the pump to study 
the patterns of coro-
nary blood flow and 
devise methods for 
its safe removal from 
the open heart. 
1950 
John Hopps, an 
electrical engineer, in-
vents the first cardiac 
pacemaker. A year 
later, Paul Zoll, MD, a 
cardiologist in Boston, 
is credited with 
building on Hopps’ 
work and developing 
an external tabletop 
pacemaker for treat-
ment of heart block. In 
1959, the first use of a 
cardiac radiofrequen-
cy pacemaker in the 
Western Hemisphere 
takes place at Yale 
under the direction 
of William W.L. Glenn, 
MD, chief of cardio-
vascular surgery.
1957  
Edward H. Hon, MD, 
and Orvan W. Hess, 
MD, publish in Sci-
ence a description of 
an electronic device 
to gauge fetal heart 
rate. Created by Hess, 
with Hon’s assistance, 
the device is first 
used at Yale New Ha-
ven Hospital in 1960.
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Center for Research Computing provides tutorials 
and training sessions in software coding for faculty 
researchers, and graduate programs have been created 
to teach data science and bioinformatics. 
In the Yale Computational Biology and Bioinformatics 
program, doctoral candidates use high-performance 
computing to investigate such biomedical questions 
as how genes work together at the molecular level 
to mediate complex biological processes. William 
Meyerson, an MD/PhD candidate in the program, is 
studying non-disease-causing mutations—which will 
contribute to the understanding of disease-causing 
mutations. In his planned career as a physician-bioin-
formatician, Meyerson wants to facilitate the adoption 
of new computer-aided decision-making tools. “ere 
are language and culture differences between doctors 
and computing experts,” he says. “My role will be to 
bridge the gap between my computational colleagues 
and my clinical colleagues.”
While many of the innovations that drive progress 
in medicine take place within the walls of medical 
schools, much of the discovery in the realm of medi-
cal technology happens in the wilds of the business 
world. at’s why we increasingly see faculty mem-
bers who have one foot planted in academia and the 
other in commerce. 
Jonathan Rothberg, the gene sequencing innovator, 
shows how this two-step is done. While he remains 
on the adjunct faculty at Yale, his day job is running 
a startup incubator based in nearby Guilford, where 
seven companies so far are targeting health care. In all 
cases, they’re developing medical devices that use deep 
learning, a form of artificial intelligence, to continu-
ally improve their performance. One of his companies, 
Butterfly Network, developed a handheld ultrasound 
device that costs less than $2,000.
Rothberg predicts that the combination of technology 
and medicine will have profound effects on the future 
of the human race—for instance, he believes that people 
will someday live to be 200 years old. “We have sequenc-
ing, we have medical records, we have high-performance 
computing, and we have AI,” he says. “We’ll understand 
the complex diseases, and we’ll be able to intervene and 
extend life.” /yale medicine magazine
Steve Hamm is a frequent contributor to Yale Medicine Magazine.
1960  
Theodore H. Maiman, 
PhD, operates the first 
optical laser at Hughes 
Research Laboratories 
in California. Lasers 
have many uses in 
medicine, including 
surgery, kidney stone 
treatment, ophthal-




ogy begins to merge 
with medical technol-
ogy; it is now used to 
store medical records, 
control instruments, 
and perform robotic 
surgery.
1971 
Paul Lauterbur, PhD, 
applies magnetic field 
gradients to create 
nuclear magnetic reso-
nance (NMR) images. 
Along with physicist 
Peter Mansfield, PhD, 
he develops MRI tech-
niques like echo-planar 
imaging. In 1979, with 
the arrival of Robert 
G. Shulman, PhD, Yale 
becomes a leader in 
magnetic resonance 
research, and Yale fac-
ulty are the first to use 
MRI to measure the 




MD, is granted the 
world’s first patent  
in the field of MRI, 
after he discovers 
how to use magnetic 
resonance imaging 
for medical diagnosis. 
By 1977, Damadian 
completes con- 
struction of the  
first whole-body  
MRI scanner.
1975  
Robert S. Ledley, MS, 
DDS, a physiolo-




(CT) scans. His device 
builds on early de-
signs by Sir Godfrey  
N. Hounsfield, a Brit-
ish electrical engineer, 





X-rays taken at dier-




liam V. Tamborlane, 
MD, professor of 
pediatrics, and Rob-
ert S. Sherwin, MD, 
professor of medicine, 
develop the insulin 
infusion pump for 
people with diabetes. 
The pump provides a 
means of maintaining 
better control over in-
sulin levels in children 
who would other- 
wise need multiple 
daily injections.
1982 
The first permanent 
artificial heart is im-
planted at the Univer-
sity of Utah. Until then 
artificial hearts had 
served as a bridge to 
transplantation. The 
heart was developed 
by Robert K. Jarvik, 
MD, who modified 
earlier models and on 
December 2, implants 
an artificial heart into 
retired dentist Barney 
Clark, who survives for 
112 days.
2015  
Stuart Weinzimer, MD, 
and colleagues at Yale 
are at the forefront 
of eorts around the 
country to develop an 
artificial pancreas. The 
closed loop system of 
devices and software 
transmits blood glu-
cose level readings to 
a device that controls 
insulin delivery.
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The disembodied living lungs in one Yale researcher’s 
lab show that a standalone bioengineered lung is 
well along the road to reality.
Pneumonia, aspiration, fluid in the lungs, and injuries 
from mechanical ventilators can severely damage the 
lungs of people who are critically ill. Transplanted 
lungs are tragically scarce and beyond the reach of 
most such patients, including those burdened by such 
chronic lung diseases as cystic fibrosis or emphysema. 
What if custom-grown new lungs were an option? 
e idea sounds like science fiction. But the disem-
bodied living lungs in one Yale researcher’s lab  
show that a bioengineered organ is well along the 
road to reality. 
“It’s an exciting time to be working in lung regen-
eration,” says Laura Niklason, MD, PhD, the Nicholas 
M. Greene Professor of Anesthesiology and professor of 
biomedical engineering. 
 “Our understanding of how the lung is put together 
is growing very rapidly right now.” 
Trained as an anesthesiologist as well as a bench sci-
entist, Niklason spent years in the ICU witnessing the 
devastating results of lung infection and damage. “Many 
organs heal, but after severe injury, lungs tend not to,” 
she says. When she arrived at Yale in 2006, she began 
working on lung regeneration; the possibility seemed 
even more far-fetched then than it does now.
Four years later, her team transplanted a regen-
erated lung into a rat; it performed effective gas 
exchange, albeit briefly. e achievement made it into 
the pages of Science in June 2010. 
ere are not nearly enough transplantable lungs 
available for the people who need them. Only about 
15% of cadaveric donors provide useable lungs, in 
part because many patients linger on ventilators and 
accumulate lung damage, including infections, prior 
to death. (Contrast that with the 88% harvest rate for 
cadaveric kidneys.) Lungs also don’t take kindly to 
transport and typically have to be transplanted within 
a few hours of harvest.
In addition to the tight supply problem, lung trans-
plant recipients face a lifetime of immunosuppres-
sive drugs to prevent their bodies from rejecting the 
donor lungs. A lung engineered from the patient’s own 
cells could circumvent the immune system and spare 
patients the risks of long-term immunosuppression. 
Fortunately, the lung makes for a more feasible bio-
engineering challenge than does a solid organ like a 
kidney or heart. e lung is mostly empty space, com-
prising a protein skeleton coated with thin cell layers 
that exchange oxygen and carbon dioxide. 
e first step to building a new lung is to partially 
dismantle an existing one. Niklason’s team has devel-
oped a reliable method using detergents, salts, and 
enzyme solutions to remove the cells from an adult 
lung. Leaving that skeleton and its dozens of attached 
protein types intact is crucial. ese proteins vary 
from one part of the lung to another, and they send 
signals that direct what kind of cells a progenitor cell 
landing on them will become. 
e second lung-regeneration step is to wash the 
protein skeleton with hundreds of millions of new cells 
that lay down fresh airways and blood vessel linings. 
Building lung  
capacity, lung-first
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If step one has left the proteins intact, the cells should 
in theory find their way to the right place.
“ere are zip codes that are built into the matrix of 
the lung,” says Micha Sam Raredon, an MD/PhD can-
didate in Niklason’s lab. “If you seed a homogenous set 
of cells … depending on where they fall on the scaffold, 
they’re going to get site-specific cues that can push 
them toward a certain phenotype.”
“Getting the cells there, physically getting them 
there, is much easier. Getting them to behave and to 
do what you want them to do—that’s the tricky part,” 
Niklason says. 
e new lung grows in a glass jar that bristles with 
tubes and connectors. Custom-made by the universi-
ty’s in-house glassblowing team, these so-called biore-
actors suspend the growing lungs amid fluid that flows 
rhythmically around them. One set of tubes pumps the 
fluid through the lung vasculature as the heart would; 
another carries fluid away to be oxygenated as it would 
be by a placenta. 
“Proper breathing motion is certainly critical for actu-
ally getting our lungs to form and getting the cells to 
differentiate the way they should,” Niklason says. “We’re 
mimicking the embryonic state of lung development.” 
“It looks exactly like what you’re picturing,” 
Raredon adds. “ey’re these pulsing organs in a glass 
jar that we’re keeping alive.” 
When might patients with devastating lung diseases 
have access to brand-new lungs of their own? A first-
in-humans implant could happen within 15 to 20 years, 
Niklason estimates. “It’s a hard problem and it’s a  
several-decade problem, and you need a lot of people 
and a lot of resources to try to tackle it,” she says.  
“I tell everybody, ‘I hope to do this before I die.’” /yale 
medicine magazine
Jenny Blair is a frequent contributor to Yale Medicine Magazine.
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Ellen Hoffman is developing a microscope that 
will enable her to look into zebrafishes’ brains. 
On a warm sunny morning last September, eight 4- 
and 5-year-olds in Phyllis Bodel Childcare Center’s 
kindergarten class on the campus of Yale School of 
Medicine (YSM) sat outside at picnic tables with their 
eyes glued skyward. In the middle of the courtyard in 
front of them a large crane was slowly lifting enormous 
crates from a giant delivery pallet to a doorway in 
the Sterling Hall of Medicine. For over an hour, these 
youngsters sat nearly still with razor-like focus on the 
large machinery, discussing what was happening—and 
what was inside those crates.
e enormous crane was unloading parts of a 
microscope into YSM, one that would be built by 
Joel Greenwood, PhD, associate research scientist in 
neuroscience and director of the Neurotechnology Core 
in YSM’s Kavli Institute for Neuroscience. Greenwood 
established the core in 2017, a design and fabrication 
facility that is free for other researchers to use. At the 
same time, Greenwood had just started to construct 
another microscope, one that also required special 
delivery of multiple component parts, a two-photon 
laser, and rigging for a large optical table. is micro-
scope was being built from scratch, and is the only one 
of its kind in New England. 
e gargantuan microscope that’s being built? One 
dedicated to the study of tiny organisms—zebrafish. 
Ellen Hoffman, MD, PhD ’14, assistant professor in the 
Child Study Center and of neuroscience at YSM, will 
use this microscope to perform whole-brain functional 
imaging in zebrafish to better understand the function 
of genes that increase the risk of autism. is micro-
scope will enable her to look into the fishes’ brains 
throughout development—their embryos are transpar-
ent—to examine brain structure in zebrafish lacking 
functional autism risk genes. Using this specialized 
microscope, Hoffman will be able to collect live images 
of the fish while watching neural signaling before, 
during, and after drug treatment. In this way, she will 
be able to glean information that wasn’t possible before 
she acquired this microscope. 
“is microscope will enable us to visualize how loss 
of function of autism risk genes leads to differences in 
neural signaling in the developing vertebrate brain in 
real time at the single-cell level,” says Hoffman.
As with other colleagues at YSM, Greenwood is 
teaching members of Hoffman’s lab to build and use 
components of the microscope while providing crucial 
oversight in the process. In this way, scientists will 
have an intricate understanding of this specialized 
piece of technology. is understanding also helps sci-
entists think critically about their work and the specif-
ics of how experiments can and should be conducted, 
Greenwood says. 
is microscope had to overcome a primary chal-
lenge of working with zebrafish—how to record the 
animal quickly and without its knowing. Hoffman’s 
microscope is a two-photon light sheet microscope, 
meaning that sheets of light rapidly “scan” through 
the entire fish brain to record whole-brain activity in 
less than one second. Traditional two-photon micro-
scopes are slow, scanning the brain point by point. 
With a small zebrafish, the animal must be held still in 
a natural position and scanned quickly enough that it 
can’t detect the light. Otherwise, its natural behaviors 
would be compromised. 
To solve this problem, Hoffman and Greenwood 
relied on existing research publications to build 
the novel instrument that will precisely answer 
Hoffman’s questions. ey modified attributes of 
existing models to make her microscope a “double 
whammy”—one that increases the speed of the light 
sheet and is also invisible to the fish. e two-photon 
A perfect day for a zebrafish
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light sheets are outside the visual spectrum of the fish, 
making the light undetectable to the animal, and the 
light can penetrate deeper, giving better resolution. 
e microscope will enable Hoffman and her team to 
see more neurons simultaneously in a live, function-
ing animal. is clarity will give her studies both 
ethological and ecological relevance.
Hoffman already knows the first experiments she 
will conduct with this microscope, which was funded 
by the National Genetics Foundation, the SPECTOR 
Fund, the Kavli Foundation, and the National 
Institute of Mental Health. She plans to study base-
line brain activity in fish that have mutant forms of 
the CNTNAP2 gene, which is strongly associated with 
autism and epilepsy in humans. Using transgenic fish 
expressing a form of green fluorescent protein that 
turns on when brain cells become active, Hoffman 
will learn what is happening at the cellular level. She 
then hopes to determine how compounds identified 
in related drug screening experiments affect brain 
signaling. For these studies, she will be able to use her 
new microscope to understand how changes occur-
ring at the circuit level in the zebrafishes’ brains 
might relate to behavioral differences resulting from 
loss of autism risk gene function.
With this new technology, Hoffman aims to answer 
fundamental questions about the mechanisms underly-
ing brain and behavioral development so she can lay the 
groundwork for developing improved treatments for 
children with developmental disabilities. In so doing, 
she may also lay the groundwork for a future scien-
tist—perhaps even one of the children admiring how 
carefully the crane’s long arm moved microscope parts 
into YSM—to develop the next generation of technolo-
gies to make life-altering discoveries. /yale medicine 
magazine
Amanda Dettmer, is an associate research scientist in the Yale Child 
Study Center and a contributor to Yale Medicine Magazine.
David Jin, gradu-







in the laboratory 
of Ellen Homan, 
MD, PhD, which 
is part of the 
Neurogenetics 
Program at the 
Yale Child Study 
Center, and is 
involved in trans-
lational research 





by jeanna lucci-canapari | matthew daley illustration
The Center for Biomedical Innovation and Technology provides 
a home for those who want to develop medical devices to meet 
unmet needs in health care, and bring them to patients. 
Have an idea to develop a novel biomedical device, 
diagnostic, or health IT app that could have big patient 
impact? ere’s a place where scientists, clinicians, 
and entrepreneurs can connect at Yale’s Center for 
Biomedical Innovation and Technology (CBIT). 
During the past five years, CBIT has developed into 
a one-stop shop for would-be biomedical innovators 
and entrepreneurs. To date, CBIT has supported more 
than 3,000 members of the Yale community and over 
200 projects that have attracted more than $24 million 
in outside funding. 
 “Yale is about getting good ideas out into the world,” 
says CBIT co-founder Mark Saltzman, PhD, Goizueta 
Foundation Professor of Biomedical and Chemical 
Engineering. “Entrepreneurship is another way to do 
that, and to make an impact.” He and Peter Schulam, 
MD, PhD, professor and chair of the Department of 
Urology, founded CBIT in 2014 in response to a cultural 
shift they saw happening in higher education. “Starting 
your own company directly out of school has become a 
more common career pathway,” says Saltzman. “ere 
is a lot of interest, but how do you get there?” 
“When Mark and I co-founded CBIT, the idea was to 
more comprehensively support not only medical device 
development in this community, but also health IT, 
diagnostics, and processes,” says Schulam. CBIT col-
laborates with the Office of Cooperative Research, 
which supports faculty and researchers in develop-
ing technology of all types. Saltzman and Schulam 
wanted to expand the support and expertise offered 
for biomedical innovation. “CBIT team members have 
multiple roles,” Schulam says. “We educate and build 
culture. We provide mentorship, and help innovators 
successfully obtain seed funding.” 
To help innovators, CBIT centers its services around 
four fundamental domains of biomedical design, 
according to Schulam. ese include the technical, 
clinical, regulatory, and business aspects of innovation. 
Setting milestones that address all four of these needs 
isn’t always intuitive to science professionals who are 
unfamiliar with venture creation. 
“Often our innovators have a technical or clinical 
background, so they are inclined to move their innova-
tion all the way to the end from a technical perspective. 
CBIT works with them to make sure they are address-
ing the appropriate clinical, market, and regulatory 
issues as they evolve the technology,” says CBIT’s 
Innovation Director Margaret Cartiera, PhD ’07. 
“You have to understand the process if you are in 
the device or health IT world and you have an idea,” 
adds Schulam. “At each step, you have to ask yourself 
whether you are meeting those four areas. If you are 
not, you have to pivot or you will end up with some-
thing that is not marketable.”
rough formal coursework, informal mentoring, 
and campus activities like hackathons, students and 
faculty can explore innovation in the health care space 
“with guardrails or without,” says Cartiera. A variety of 
partnerships within the university and beyond keeps 
innovators on the path to success. 
Where scientists and 
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For one-on-one mentoring, CBIT looks to industry 
to match innovators with experienced entrepreneurs. 
Co-Executive Director Michael Dempsey, having built 
three medical device companies, brings that perspec-
tive to CBIT.
“We work with the investigator on market analysis, 
while we simultaneously teach the investigator how to 
do it,” Dempsey says. “CBIT’s whole notion of mentor-
ing is pretty intimate. You have to find the right com-
bination of people who will spend a lot of time together 
to make the project successful.”
Before he became co-executive director of CBIT, 
Chris Loose, who has a PhD in chemical engineer-
ing from MIT, had launched a successful biomedical 
venture of his own. At Yale, “I was eager to help stu-
dents and faculty do the same,” he says. “One of the 
real powers of CBIT is that we put MDs with business 
students with undergrads and others to create highly 
diverse collaborations that are critical for innova-
tion.” is collaboration extends to formal coursework 
offered by CBIT. Loose teaches a course called Creating 
Health Care Ventures, in which students from across 
Yale work on building business and product plans. 
Another well-attended course, Medical Device 
Design and Innovation, is co-sponsored by one of 
CBIT’s crucial partners, the Center for Engineering 
Innovation and Design, which also works with CBIT to 
build prototypes of the medical devices created. 
CBIT also holds an annual hackathon, in which 
teams examine unmet medical needs and connect with 
experienced entrepreneurs, care providers, adminis-
trators, and others capable of coaching them toward 
generating new solutions. “We bring hundreds of 
people together across dozens of institutions, including 
internationally,” says Loose. To date, CBIT has orga-
nized six hackathons around campus. 
CBIT also develops funding sources for biomedi-
cal innovations. e group worked with the state of 
Connecticut to create Bio Pipeline CT, a collaboration 
with Yale, the University of Connecticut, Quinnipiac 
University, and the Connecticut Innovations agency 
which administers the Connecticut Bioscience 
Innovation Fund. CBIT founded a $1 million, two-
year initiative that provides groups of faculty and 
students, or small start-up companies affiliated with 
any Connecticut university, with up to $30,000 per 
project of gap funding. For every dollar given, says 
Loose, “$14 in follow-on funding was raised by these 
companies supported by the Bio Pipeline to continue 
to advance their ideas, and four have gone to human 
trials.” e program has just been renewed for another 
$1 million, two-year round of funding.
Saltzman’s own project was one of the first to be 
funded by the Bio Pipeline. For guidance, Saltzman 
and his colleague, Michael Girardi, MD ’92, professor 
of dermatology, turned to fellow experts at CBIT. ey 
developed a biodegradable bioadhesive sunscreen using 
nanoparticle technology that does not absorb into the 
skin, unlike most commercially available sunscreens 
that may cause potentially harmful side effects. “We 
have a start-up company now that is going to put it 
into production, and hopefully into bottles and onto 
shelves,” Saltzman says.
Now that the appetite for entrepreneurship has 
taken hold, the next step for CBIT is to continue 
building collaborations with campus organizations. 
“CBIT is docking into Tsai CITY,” says Schulam. Tsai 
CITY (Center for Innovative inking at Yale), where 
Schulam acts as faculty director, operates as a portal 
and connector for organizations such as CBIT across 
the university. “CBIT is one component within a larger 
ecosystem of innovation,” he says. “rough Tsai CITY, 
we are creating interconnectivity, collaboration, and a 
multidisciplinary approach to innovation.”
Because of CBIT’s success on campus and in the 
world beyond Yale, the idea and process remain at the 
heart of its mission. “We want our community to know 
that if you see an unmet clinical need and you have an 
idea, you should run with that idea. e exploration 
itself is useful, even if it doesn’t end in a company,” 
says Schulam. /yale medicine magazine
Jeanna Lucci-Canapari is a frequent contributor to Yale Medicine 
Magazine.
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In January 2019, Yale School of Medicine (YSM) com-
pleted a renovation project that included 14 new clini-
cal training rooms equipped with ultrasound tablet 
devices. is technology did not exist in the former 
practice space and its addition has already had positive 
results for medical education.
ese changes are particularly evident in the 
Clinical Skills Course, which spans the first 18 months 
for all medical students. In it, students learn how to 
communicate with and examine patients and develop 
their clinical reasoning skills. 
Jaideep Talwalkar, MD, associate professor of medi-
cine and of pediatrics and director of clinical skills 
explains, “e Clinical Skills Course has always been 
hands-on, but what is novel about using ultrasound 
is the added layer of visualization in real time that 
ultrasound provides, simultaneous with other learning 
modalities that we’ve already been using.” 
Rachel Liu, MBBCh, assistant professor of emer-
gency medicine and director of point-of-care ultra-
sound education, is excited about the educational 
opportunities the renovation makes possible.  
Liu introduced point-of-care ultrasound into the  
longitudinal preclerkship curriculum six years ago  
with a pilot program converted into a preclerkship 
elective. She believes point-of-care ultrasound’s  
central mission is to aid students in understanding 
how to integrate anatomy, physiology, and pathol-
ogy while learning physical examination skills. is 
approach is different from ultrasound as a diagnostic 
tool that may be introduced in fourth-year electives, 
residency, and fellowship training. “Point-of-care 
ultrasound holds distinct roles in both education  
and patient care, but it is not a replacement for  
imaging performed by radiologists or other medical 
specialists,” Liu says. 
When Liu developed the preclerkship pilot, she combed 
the YSM curriculum to pair it with ultrasound uses. She 
then worked with Talwalkar and Joseph Donroe, MD, 
MPH, assistant professor of medicine and director of phys-
ical examination education, to bring ultrasound into the 
Clinical Skills Course. Donroe, who teaches small groups 
in Liu’s curriculum, provides examples of how ultrasound 
is enabling him and his colleagues to better instruct stu-
dents in the art of physical examination. 
In the past, faculty would have students practice pal-
pating the abdomen to look for the liver, but it was often 
difficult for students to understand exactly what they 
were touching. Now, by coupling the physical exam with 
ultrasound, students can literally see the liver, making 
the experience more concrete and memorable. A similar 
effect is achieved when students can see heart valves 
opening and closing in real time using ultrasound as they 
listen to a heartbeat with a stethoscope. 
Elizabeth Woo, a third-year MD/PhD student, is 
grateful to have been in the ultrasound longitudinal 
course. She describes how during her preclerkship 
years, ultrasound “allowed me to better contextualize 
human anatomy as well as seeing the ‘why’ to different 
clinical maneuvers.”
Second-year medical student Pablo Delis, who is tak-
ing the ultrasound elective, echoes Woo’s praise for the 
course. “Being able to see a heart beating, bowel peristal-
sing, and lung pleura sliding in real time has been invalu-
able in solidifying my understanding of these organs. 
Knowing I am competent in performing essential ultra-
sound studies and interpreting the images taken by other 
medical team members has granted me a level of confi-
dence I believe is rare among first-year medical students.”
With the new space and equipment, students can 
now practice ultrasound in small groups. is oppor-
tunity will make it easier for students to develop their 
Honing clinical skills with ultrasound
Ultrasound augments learning opportunities for 
medical students.
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skills and take advantage of peer-to-peer teaching. 
Such shared learning had not been possible previously 
when students used vendor-loaned equipment at vari-
ous locations. 
Sixteen first-year students and seven second-year 
students who participated in the longitudinal ultra-
sound elective have been certified to help train peers. 
Michael Schwartz, PhD, associate professor of neuro-
science and associate dean for curriculum, believes 
this peer-to-peer training aids students’ development.
Students and faculty are enthusiastic about inte-
grating ultrasound into the medical education curricu-
lum, does it actually improve learning? Liu, Donroe, 
and Chris Moore, MD, associate professor of emergency 
medicine and section chief of emergency ultrasound, 
are conducting research to find out. Most studies 
involve tests specific to ultrasound teaching. However, 
Liu says, “nothing has really looked at the effect of 
ultrasound teaching to the more general curriculum, 
and this is the part that is important.” 
In her research to date, Liu looked at students’ 
qualifying examinations and the examinations that all 
students in every medical school must pass (objective 
structured clinical examinations or OSCEs, and United 
States Medical Licensing Examinations or USMLEs). 
“Overall we found that the area where ultrasound 
teaching seemed to have a beneficial statistical signifi-
cance was in the physical examination performance 
of their OSCE.” ese findings are limited by a small 
sample size. e YSM curriculum changed in 2015, and 
Liu was able to obtain only two years of data from the 
old curriculum. She plans to repeat the study, as she 
will soon have access to up to four years of data from 
the new YSM curriculum.
Evidence that the ultrasound device is enhanc-
ing education is critical. As Schwartz says, “If two 
years later we are talking about the technology of 
ultrasound, we have missed the boat. e key is not a 
technological tour de force; it is how the technology 
enhances education.”
Liu says that when the Department of Emergency 
Medicine offers point-of-care ultrasound train-
ing courses to faculty, “we routinely have attendees 
from many different specialties.” Both Talwalkar and 
Donroe attended these courses. Before his initial train-
ing, Talwalkar spent a month-long sabbatical in late 
2018 in Santiago, Chile, with Liu’s colleague, Pablo 
Aguilera, MD, Chief of Emergency Medicine, Pontificia 
Universidad Católica de Chile. Talwalkar’s main goal 
was to learn the basics of ultrasound because, as he 
explains, he has been helping “to build ultrasound into 
the YSM clinical skills curriculum, but had absolutely 
no ability to help out with the teaching. I was more 
novice than the students.” 
Like Talwalkar, many YSM doctors and residents 
are new to point-of-care ultrasound and eager for 
training because the technology’s widespread use is a 
fairly recent development. Since returning from Chile, 
Talwalkar has used ultrasound in clinic and on hospital 
rounds to highlight its uses with residents and stu-
dents. He says, “Learners are extremely enthusiastic 
about using it. ey recognize the potential applica-
tions, but many residents have had little exposure.” 
Ultrasound training is standard in such residen-
cies as emergency medicine, obstetrics, and radiology, 
but other specialties are just starting to incorporate it 
into their training. Liu plans to collaborate with YSM’s 
Teaching and Learning Center to create more faculty 
development opportunities to train future educators. 
Gail D’Onofrio, MD, MS, chair and professor of emer-
gency medicine, reflects on the critical role of ultra-
sound in emergency medicine and as an educational 
tool. “Ultrasound has become an essential tool in the 
ED as we evaluate patients with acute life-threatening 
illnesses and injuries. Dr. Liu is a remarkable trailblazer 
in educating students, residents, and faculty in the skill 
of ultrasound. Her passion, expertise, and creativity 
are apparent in her teaching. She is world-renowned 
for helping to create the innovative SonoGames® and 
SonoSlam™ as pedagogical exercises. We are incred-
ibly fortunate to have her here at Yale.” /yale medicine 
magazine
Abby Roth is a communications ocer in the Oce of Education and 
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Yale School of Engineering and Applied Science 
combines medicine, engineering, and 
problem-solving to increase the reliability 
of orthopaedic devices.
Maddy O’Neal held a shiny titanium screw in her hand 
while studying a computer model of the device on the 
screen in front of her, looking for potential weaknesses 
once the screw is put in someone’s body to repair a 
broken hip. “ere are lots of ways these can fail,” says 
O’Neal, a senior majoring in biomedical engineering. 
“e screws can come out and float around in some-
one’s body. ere are a lot of moving parts, which is a 
good thing and a bad thing.”
e device O’Neal is evaluating is one of several 
types designed to help mend broken hips that have one 
feature in common—a history of breaking. Improving 
those flawed devices is a challenge that O’Neal and 
her classmates have attempted to resolve this semes-
ter. O’Neal is among 20 undergraduate students in the 
medical device design class, which is offered by Yale 
School of Engineering and Applied Science. e course 
combines medicine, engineering, and problem-solving 
with the goal of improving unreliable devices.
Broken screws are a problem. In the case of one 
model, the shaft that runs along the femur can fail 
where the bone is broken. e bone is not supporting 
the patient’s weight at that point—the metal shaft must 
do it. Sometimes the shaft is not up to the task, says 
Alexander Crich, a senior majoring in biomedical engi-
neering and mechanical engineering, as he held the 
implant in front of him.
Students do much of their work with computer 
modeling software, but real-world experiences are an 
important part of the class. Accompanying one of the 
course directors, Daniel Wiznia, MD, in the operating 
room, students get a sense of the surgery in which the 
implants and screws are installed. 
Another lecture features a presentation from 
Kristaps J. Keggi, MD ’59. A professor emeritus and 
senior research scientist of orthopaedics and rehabili-
tation in the medical school, Keggi has performed over 
ten thousand hip-replacement surgeries and consulted 
for companies that produce the implants. He told stu-
dents the work they are doing has been going on since 
the 19th century, when early implants were made of 
ivory or wood. Keggi told students that physicians 
have played a key role in improving implants. While 
the students are using sophisticated computer software 
for their projects, Keggi says he once sketched the pre-
liminary design for an implant on a napkin in a restau-
rant while on a business trip in Cleveland. 
“We learned as we were using them,” Keggi says of 
the implants.
is is the fifth year the engineering school has 
offered the medical device design class. In previous 
years, students were asked to come up with an  
idea for a new device. Proposals included a lab coat 
sanitizer and technology aimed at helping people 
recover from concussions.
Steven Tommasini, PhD, a research scientist of 
orthopaedic rehabilitation at Yale School of Medicine 
who is co-teaching this semester’s class, says that 
this year students are focused on improving existing 
devices. Hip implants were chosen because procedures 
for that part of the body are common, Tommasini says.
“Compared to other implants they are relatively simple. 
Also, they are in a spot that is the most heavily loaded 
spot in the body, so failure is not uncommon,” he says.
Students are divided into teams charged with 
studying one of five different implants used to treat 
Engineering innovation
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hip fractures. Each of these devices is on the market, 
but they have unique strengths and weaknesses for 
treating different fracture patterns, Tommasini says. 
e students use computer modeling to simulate the 
stresses on each implant to figure out where and how it 
fails. With that information, they can turn their atten-
tion to designing a better implant.
After studying the hip screws, the students model 
different kinds of artificial hip joints used for total 
replacement procedures. After that, they can choose 
their own idea for the final part of the class, Tommasini 
says. He teaches the class with Wiznia, who is an assis-
tant professor of orthopaedics at the medical school as 
well as an assistant professor of mechanical engineering 
and materials science at Yale School of Engineering.
Wiznia says students are studying how well these 
hip implants treat an uncommon injury called a subtro-
chanteric fracture. is kind of fracture can result from 
an accident but is also seen in patients taking bisphos-
phonate therapy for osteoporosis. Although the implants 
are customarily used to fix this kind of fracture, Wiznia 
says that the implants were not designed for it. “ey do 
an okay job, but they have a failure rate.”
e class was not going to be held in the spring 
semester because of a scheduling conflict but was 
put on the schedule anyway after widespread stu-
dent demand. “I was excited to take a class where you 
design something, get your hands dirty, and solve a 
problem,” says Matan Cutler, a sophomore.
 “ey needed someone to take over this class 
and we’re hoping we can keep doing it because we’re 
having fun,” Tommasini says. “is is one of the few 
classes where you get to build something and be crea-
tive. Engineering students don’t get to do that a lot.”
Wiznia says the class is a good way of bringing 
together two disciplines that can help each other.  
“As an engineer, you are a problem solver,” he says. “As 
a surgeon, you are constantly trying to improve medi-
cal outcomes. is is a terrific fit for an engineer.”
Most of the students who take the class are in the 
engineering department. Lauren Ribordy, a senior 
majoring in biomedical engineering, says she was 
excited to use the computer modeling technology but 
also found it sobering to find out more about bone 
fractures. “ere is a lot of potential to help people,” 
Ribordy says. “It should not be a case of ‘We hope it 
will work.’ Can we model it to see if it will fail before 
we give it to a patient?”
O’Neal says she wants to go into the medical field 
and work with implants. Initially she was interested 
in prosthetics but shifted her interest to hip devices, 
in part because of the experience of her grandmother 
who, she says, had both knees and a hip replaced.  
She also sees a growing need for better technology to 
repair joints.
“is is really what I want to do, implants or some-
thing like that. ey are so cool,” O’Neal says. “As people 
get older our bodies are more likely to fracture; and  
now athletes are getting knee replacements that need to 
stay in place for 30 or 40 years. With people living lon-
ger, implants won’t be going anywhere.” /yale medicine 
magazine
Ken Byron is a contributor to Yale Medicine Magazine.
PREVIOUS SPREAD, LEFT
Students from the engineering 
school’s medical device design 
class examine an implant designed 
to treat hip fractures. The cur-
riculum emphasizes out-of-the box 
problem solving for rare injuries for 
which there is no financial incen-
tive to develop new products.  
Clockwise from top left: Sofia Gri; 
Sofia Gri (L) and Matan Cutler 
(R); Maddy O’Neal (L) and Fadzai 
Mataru (R); Sofia Gri (L), Dan 
Wiznia (M), and Matan Cutler (R); 
Lauren Ribordy (L) and Steven 
Tommasini (R); Steven Tommasini.
. 
PREVIOUS SPREAD, RIGHT
Daniel Wiznia, one of the class’s 
two instructors and faculty at Yale 
School of Medicine (YSM), dis-
cusses one of the challenges facing 
designers when it comes to im-
proving medical devices with stu-
dent Alex Critch. Wiznia graduated 
Yale with a degree in Mechanical 
Engineering in 2006, and it remains 
an important component of how 
he views medicine at YSM.
ABOVE The last hundred years or 
so saw huge jumps with innova-
tion as materials research made 
durable equipment more acces-
sible and easily produced. Since 
that time, advances in ceramics 
and 3D printing technologies 
have made it possible to improve 
devices. This hip screw, or “sliding” 
hip screw, originated in the 1960s 
and still has excellent outcomes in 
most cases.
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When skin-deep is 
all you need
Working with faculty at Yale School of Medicine’s 
Department of Dermatology, two Yale undergrads 
built a device that’s helping doctors diagnose 
skin conditions from afar.
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Elizabeth Asai, Yale College ’13, never dreamed she 
would one day co-found and run her own company. 
To her, entrepreneurship seemed too chaotic a way to 
make a living. “I thought I’d go to medical school or 
work for a larger tech company,” Asai says. 
Fate intervened in 2011 when Asai and fellow Yale 
undergrad Elliot Swart entered a Boston-based student 
contest to build a primary-care medical device. e 
contest offered large cash prizes so winners could turn 
their prototypes into marketable products. 
Before the contest, the pair—Asai was a biomedi-
cal engineering student, Swart was studying electrical 
engineering and computer science—had been working 
on what they now acknowledge was an overly ambi-
tious project. ey were trying to develop a probe that 
used 3D imaging technology to assess the texture and 
elasticity of such internal tissues as tumors. 
Realizing their product would not fit the primary-
care focus of the contest, Swart and Asai shifted gears. 
ey decided to use knowledge they’d acquired in their 
first project to create a new, simpler device that took 
3D pictures of skin to assist dermatology diagnoses. 
Asai and Swart’s instincts proved spot on—their 
new device won second prize and $100,000. Key to 
the pair’s second-place finish was assistance from 
Yale School of Medicine’s Department of Dermatology. 
Doctors there fast-tracked a clinical study of the prod-
uct involving 50 patients, producing results in just four 
months, Asai says. e 30-page writeup documented 
that their product works—a vital piece of their contest 
submission, Asai says.
Swart and Asai used the money to further develop 
their idea. e next year they founded a company they 
dubbed 3Derm Systems, evoking the firm’s combina-
tion of 3D imaging and dermatology. 
Seven years later, 3Derm is thriving. e Boston-
based company has a network of over 250 primary-care 
physicians using its 3D imaging and telemedicine prod-
ucts, Asai says. She is the company’s CEO, while Swart 
is its chief technology officer. e pair, now both 27, 
express deep satisfaction with the company’s success.
“I can definitely say it’s been a rewarding experience 
taking a product all the way through its life cycle, from 
its inception and experimentation, to commercializa-
tion and getting to see patients use it,” says Swart, who 
got so involved in the firm that he left Yale shortly 
before finishing his degree. “I think it was more 
rewarding to me than I would have anticipated.”
Yale was “very important” to their success, 
Asai says. In addition to early encouragement and 
assistance from the engineering department and Yale 
School of Medicine, the school also helped with the 
business side. “We knew the engineering and clinical 
needs,” Asai says. “But we really didn’t know how to 
pair that with a business model.”
Yale Entrepreneurial Institute paired them with an 
experienced serial entrepreneur who provided a crash 
course in business. He also introduced them to Blue 
Cross Blue Shield, which became and remains their 
biggest investor. 
Over time, 3Derm’s product has evolved from 
straight 3D imaging of skin into a cloud-based der-
matology platform, Swart says. Doctors who sign up 
receive one of the firm’s proprietary 3D cameras. When 
they see a problematic lesion or skin condition, they 
take a photo that is uploaded into the cloud, Asai says. 
Dermatologists chosen by the primary-care offices 
then examine the cases remotely to determine whether 
the patient needs to be seen in person. 
“is is not dermatology in a box, where we have a 
room full of dermatologists reading cases all day,” Asai 
says. “All of the dermatologists we work with are out 
seeing patients in person.”
e company guarantees an answer within 72 hours, 
but typically provides one in 12 hours, she says. at’s 
much faster than scheduling appointments with der-
matologists, who have wait times as long as 100 days. 
It also saves money because dermatologists conclude in 
54% of cases that the patient can be treated in primary 
care, eliminating the need for an office visit. And when 
a skin issue is flagged, diagnosis and treatment can 
arrive faster, saving money and lives. 
3Derm may have come a long way, but it is just get-
ting started, Asai says. e firm is hard at work devel-
oping algorithms with diagnostic and triage functions, 
avoiding the need for referrals. One algorithm would 
help manage psoriasis, while the other will do the 
same for skin lesions. e firm expects to deploy one of 
the systems in the near future, Asai says. 
3Derm remains privately held with no near-term 
plans to go public. Even discussing such a development 
is premature. “I think it is far enough in the future that 
we laugh when we hear that question,” she says. /yale 
medicine magazine
Christopher Homan is a frequent contributor to Yale Medicine 
Magazine.
35Summer 2019
Scratching the surface: 
Metallic glass implants
jenny blair, md ’04 | harold shapiro photo
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fashioned from a 









Artificial joints, blood-vessel stents, bone screws, 
and other implanted objects—crucial tools to help 
patients—carry risks related to the materials they’re 
made of. Valves and stents, for example, can provoke 
an inflammatory reaction that leads to deadly clotting. 
Joint replacements may gradually loosen and require 
replacement. And any implant can cause infection.
Such devices entail engineering tradeoffs: utility 
versus the strengths and weaknesses of their com-
ponent materials. But a class of biomaterials called 
bulk metallic glasses could transform that calculus for 
future implanted medical devices, as well as for a host 
of other engineered objects. Found nowhere else in 
nature, these novel alloys may overcome many stub-
born problems associated with today’s implants.
Shiny, gray, and pliable, bulk metallic glasses 
resemble ordinary metals but are stronger and harder 
than steel. ey are nontoxic and resist corrosion 
and wear, making them well suited to dwell inside 
the body. ey are elastic enough to change form and 
spring back with ease. And they are easily shaped. 
“Usually, metals processing is a big pain. It’s kind 
of shocking—even 3D printing of metals is a big pain,” 
says materials scientist Jan Schroers, PhD, professor of 
mechanical engineering and materials science. “Metallic 
glasses have this ability to be formed like plastics.”
For example, when heated to temperatures achiev-
able in a kitchen oven, a platinum-based bulk metallic 
glass softens to what Schroers describes as the consis-
tency of refrigerated honey. “It doesn’t really deform 
by itself under its own weight, but it’s soft enough [that 
with modest] force you can deform it,” Schroers says.
In a cross-campus collaboration that has their 
lab personnel learning both metallurgic and wet-lab 
techniques, Schroers and emis Kyriakides, PhD, 
associate professor of pathology and biomedical engi-
neering at Yale School of Engineering and Applied 
Science, are exploring how bulk metallic glasses per-
form as biomaterials. 
For one thing, the materials are largely harmless  
to mammalian cells yet hostile to bacteria. is prop-
erty might make them useful as an antibacterial 
coating on artificial joints, surgical instruments, or 
hospital doorknobs. 
Metallic glasses can also exert a druglike effect. 
When cells interact with the surfaces of implanted 
foreign bodies, they may go down the path of inflam-
mation and rejection, or alternatively, toward a more 
desirable repair-like response. Which path the cells 
choose depends in part on the object’s tiniest surface 
features—its nanotopography. ese surface irregulari-
ties attract nearby proteins, which in turn influence 
passing cells in various ways. Kyriakides and Schroers 
can manipulate these cell behaviors by molding specific 
patterns onto the surface of a metallic glass.
“We can dial in whatever we want to create in terms 
of the surface—they could be nanopatterned, they 
could be porous,” Kyriakides says. “ese are [abilities] 
that are usually restricted to polymers, and we can do 
it with metals.”
at alone makes bulk metallic glasses “a fantas-
tic toolbox,” Schroers says. “You can design cellular 
responses that are desirable for a specific application.”
One such application could be a coronary artery 
stent. Many stents on the market today are impreg-
nated with a drug that diffuses into the body over time 
to prevent clotting and formation of fibrous deposits. 
But a bulk metallic glass stent with the right nanoto-
pography could exert a similar effect, eliminating the 
need for a drug. 
A class of biomaterials called bulk metallic glasses 
could transform future implanted medical devices and 
other engineered objects.
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In orthopaedics, alloys made from calcium, magne-
sium, and phosphorus may gradually disintegrate in the 
body, a useful property for some types of bone hard-
ware. Bulk metallic glasses can also be formed as strong, 
light foams—picture a solidified sponge—the density of 
which matches that of bone. at similarity is important 
because conventional joint implants tend to be stiffer 
than bone and absorb too much impact, allowing the 
surrounding bone to atrophy from disuse and resulting in 
a loosened, malfunctioning joint. An implant made from 
a metallic glass foam could avert those complications.
e term glass refers to a material whose atoms 
are arranged in an irregular non-crystalline pattern, 
and which reacts to heating by becoming viscous. To 
the eye and hand, metallic glasses look identical to 
ordinary metal. But familiar metal objects’ atomic 
structure is crystalline, comprising rows of atoms 
bonded in a lattice. Metallic glasses are more like a liq-
uid in which chaotically moving homogeneous atoms 
have been frozen in time. 
at homogeneity brings major advantages. 
Ordinary metal alloys’ crystals meet one another along 
countless microscopic edges called grain boundaries, 
which are vulnerable to slippage and corrosion. By 
contrast, metallic glasses are amorphous, homoge-
neous, and uniform in all directions throughout, mak-
ing it harder for corrosive processes to gain a foothold. 
Bulk metallic glasses are a brand-new material, 
according to Schroers. On our planet, at least, the co-
occurrence of different metallic elements in a heated 
material that is abruptly cooled to form a glass has little 
or no precedent. (e closest analogue is volcanic glass, 
which consists mostly of silicon and oxygen, not metals.) 
Oddly enough, cells survive and thrive on the new 
exotic materials. ey seem especially at home on 
alloys based on the pricy element platinum, according 
to Kyriakides: “Our cells have pretty expensive taste,” 
he quips. 
In 2014, Schroers founded a company, Supercool 
Metals, based on his patented Yale-owned technique 
for shaping bulk metallic glasses that can be used in 
modified manufacturing operations typically used in 
plastics processing. 
“[We have] commercialized the ability to make very 
complicated shapes you can’t make with any other pro-
cess, in this material that’s very attractive for a large 
range of applications,” he says. e company is working 
with NASA to develop parts for robots and satellites, and 
has developed a cellphone case with built-in flexible 
buttons that may allow the development of waterproof 
phones. Supercool Metals also manufactures tiny com-
ponents for high-end watches.
Bulk metallic glasses are not ready for biomedical 
use just yet, but it might not take long before they are. 
In 2017, Kyriakides and Schroers built a glucose sensor 
from a platinum-based bulk metallic glass that is much 
more accurate than conventional sensors. Kyriakides 
estimates that such a sensor could be developed for 
clinical use within five years. 
“We’re hoping that when people see our results, 
they can get excited about using these materials,” 
Kyriakides says. “We’ve barely scratched the sur-
face.” /yale medicine magazine
Jenny Blair is a frequent contributor to Yale Medicine Magazine.
Themis Kyriakides
“We’re hoping that when 
people see our results, they can get excited 
about using these materials. 
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In mid-March, the hall-
way that leads down the 
L-wing of the Sterling 
Hall of Medicine through 
the Rotunda to the his-
toric Beaumont Room 
saw the opening of an 
exhibit of portraits. e 
bulletin boards and his-
toric paintings usually on 
those walls gave way to 
about 30 archival-quality 
photographs of women 
faculty members, on dis-
play as part of an exhibit 
A new exhibit aims to show the 
 school as it is, not as it was.
By John Curtis
Art in Public Spaces: 
A mirror on the community
sponsored by the recently 
formed Committee on Art 
in Public Spaces (CAPS) 
at Yale School of Medicine 
(YSM). Over the course 
of the next year, images 
from the exhibit will rotate 
in order to include more 
women faculty, including 
those at different points 
in their academic career. 
Among the portraits 
hang empty frames that 
ask questions, including: 
“Who is missing? How do 
we celebrate all women 
at YSM?” and “If you 
could offer advice to your 
younger self, what would 
you say? What would you 
say to inspire the next 
generation of women in 
any profession?”
For most of its 200-plus 
years, the medical school 
has mirrored the patri-
archal society in which it 
existed. e school’s first 
women, Louise Farnam, 
Helen May Scoville, and 
Lillian Nye, matriculated 
just over 100 years ago. e 
first Black woman, Beatrix 
Ann Hamburg, was admit-
ted in the late 1940s. e 
first Black man, Cortlandt 
Van Rensselaer Creed, 
graduated from the medical 
school in 1857, but over the 
next 100 years few followed 
him. Since the mid-1990s, 
women have made up half 
of each medical school 
class. Women and minori-
ties have also increased 
their presence as faculty 
members. Faculty, stu-
dents, and staff—and such 
groups as the Committee 
on Diversity, Inclusivity, 
and Social Justice; 
Minority Organization for 
Retention and Expansion; 
and Status of Women in 
Medicine, have called 
Merle Waxman (fore-
ground), Yale School of 
Medicine’s associate dean 
of women in medicine,  
and the school ombudsper-
son, and Chenee Gallaher  
(background) of the 
school’s oce of Di-
versity, Inclusion, and 
Community Engagement, 
examine portraits from 
the school’s “Aperture: 
Portraits of Women Faculty 
in Medicine” exhibit.  
Open to the public, the 





for public-facing art that 
reflects those changes.
As an example of the 
lack of diversity, they 
point to the only art col-
lection on permanent 
display in the Sterling 
Hall of Medicine—paint-
ings of past deans, all of 
them white men. “ose 
portraits are definitely 
central to the conversa-
tion,” said Darin Latimore, 
MD, deputy dean and chief 
diversity officer. “Not just 
faculty, but students, staff, 
and our patients, are clear 
on what our walls should 
represent and who they 
should represent.”
“Everyone is think-
ing about these issues,” 
said Anna Reisman, MD, 
associate professor of 
medicine and director 
of the Program for the 
Humanities in Medicine. 
Reconsideration of historic 
images—such as a statue of 
Robert E. Lee or a portrait 
of John Calhoun—has roiled 
communities around the 
country, including Yale.
Latimore and Reisman 
are co-chairs of CAPS, 
which was formed last 
year. e interest was such 
that more than 100 people 
responded to the commit-
tee’s call for volunteers 
last year. Two subcom-
mittees were formed—one 
will identify spaces and 
develop themes for rotat-
ing exhibits, and the other 
will articulate the values 
the permanent or long-
term art should embody.
e core executive team 
also includes Melissa Grafe, 
PhD, the John R. Bumstead 
Librarian for Medical 
History; Jill Max, MS, 
senior communications 
officer at YSM; and Jennifer 
Reynolds-Kaye, PhD, 
curator of education and 
academic outreach at the 
Yale Center for British Art. 
“Each of us brings some 
kind of unique expertise 
that has driven this project 
forward,” Latimore said.
e committee is still 
considering ideas for 
future exhibits, as well 
as alternate spaces. “I’m 
pushing for Café Med,” said 
Reisman, “and there are 
many, many hallways here.”
As to their goals for this 
inaugural display, Latimore 
said, “I am hoping that it 
really will cause a conver-
sation about Yale’s past, 
present, and future.”
“What is especially great 
about this hallway is that 
it leads to the Beaumont 
Room, which is a gathering 
place for so many groups, 
including medical school 
and residency applicants—
people who are not yet part 
of this institution but may 
be considering becoming 
part of it,” said Reisman. 
“e exhibits will say that 
this is a place where people 
are open to change.”
Laura Ment, at left; Valen-
tina Greco, below; and Yetsa 
Tuakli-Wosornu, at bottom, 
are three of the women 
featured in the first round of 





















A champion for 
human rights gives back 
»
 . ,  ’, is directing $5 million 
from his estate to Yale School of Public Health to cre-
ate an endowed professorship to support teaching and 
research on improving LGBTQ mental health.
the LGBTQ community and can 
erode healthy relationships and 
behaviors. A clinical psycholo-
gist, Pachankis is internationally 
known for his development of 
novel psychosocial interventions 
to improve mental health in 
LGBTQ communities.
“John is just so energetic and 
productive on the issue of com-
ing out,” said Kessler. “I’m very 
supportive of his work not only 
in this country but internation-
ally, which is really unbeliev-
able. People around the world 
are dealing with issues related to 
coming out and John is studying 
how it affects them in a scientific 
and rigorous manner, which is 
very impressive.”
Kessler also is directing 
$5 million from his estate to Yale 
School of Public Health (YSPH), 
part of which is intended for  
the creation of a David R. Kessler 
Endowed Professorship. e 
professorship and accompanying 
resource fund will support teach-
ing and research associated with 
improving LGBTQ mental health.
e majority of the world still 
lives in homophobic and trans-
phobic conditions, including 
many areas of the United States, 
said Pachankis. In some states 
and in some countries, so-called 
conversion therapy is common 
to try to turn gay people straight, 
he said.
“As a stigmatized minority in 
society, people who identify as 
LGBTQ are subject to continuous 
assaults on their self-esteem and 
sense of belonging in their fami-
lies, schools, and workplaces,” 
As a psychiatrist, Yale School 
of Medicine alumnus David R. 
Kessler, MD ’55, understands 
the swirling mix of anxiety and 
fear that can consume individu-
als who identify as part of the 
LGBTQ community during their 
struggle to come out about their 
sexual orientation.
Kessler is not only trained 
in such knowledge, he lived it. 
From the intense anxiety attacks 
he suffered as a closeted gay stu-
dent in the 1950s to the fears of 
persecution he and other clos-
eted gay doctors shared in the 
1970s, Kessler lived through a 
turbulent time for LGBTQ people 
in American history.
Now retired and living on the 
West Coast, Kessler, who pub-
licly affirmed his sexuality in 
1978, wants to help others who 
may be struggling to come out 
or who are dealing with stigma, 
oppression, and other issues that 
affect their mental health.
“Coming out was a fantastic 
experience for me and that’s 
why I’m so interested in help-
ing others, because I realized 
from my own experience what a 
meaningful, life-changing event 
it is,” said Kessler (no relation to 
former Yale School of Medicine 
Dean David Aaron Kessler).
Kessler recently made a gift 
of $200,000 to support the 
work of Yale School of Public 
Health Associate Professor John 
Pachankis, PhD, and his Esteem 
Research Group, which is dedi-
cated to addressing the depres-
sion, anxiety, and substance use 
that disproportionately affect 
ymm.yale.edu42
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A recent designation 
by David R. Kessler 
ensures that the ad-
vocacy work he did on 
behalf of LGBTQ men-
tal wellness continues 
long into the future.
manual, then the third edition of 
the Diagnostics and Statistical 
Manual of Mental Disorders or 
DSM III, classified homosexuality 
as a mental illness and perversion.
“I had been reading all this 
nonsense psychiatrists had writ-
ten about how sick gay people 
are and I got so angry I couldn’t 
stand it anymore,” Kessler 
recalled. “I just said, ‘at’s it! 
We need to organize and put an 
end to this stuff and let people 
know who we are and that there 
are gay people everywhere and 
we’re just like everyone else.’ ”
Despite San Francisco’s bur-
geoning gay community, orga-
nizing wasn’t easy, Kessler said. 
Other medical professionals  
were scared of losing patients 
if their homosexuality became 
said Sten H. Vermund, MD, PhD, 
dean and Anna M.R. Lauder 
Professor of Public Health, who 
has made improving LGBTQ 
mental health a priority of his 
administration. “I cannot think 
of a higher-impact program in 
which Dr. Kessler could invest 
than Dr. Pachankis’ Esteem 
Program. Kessler’s generosity 
will ensure that LGBTQ mental 
health research geared toward 
preventive and therapeutic 
interventions will be part of 
YSPH under Pachankis’ leader-
ship and in perpetuity.”
Pachankis’ research is dedi-
cated to delivering effective 
LGBTQ-affirming mental health 
treatments to vulnerable popu-
lations in the United States and 
around the world, such as those 
in rural Appalachia, China, and 
Eastern Europe. Some of the 
programs Pachankis has initi-
ated since arriving at Yale in 
2013 involve improving training  
for mental health providers, 
delivering mental health treat-
ment via the internet and mobile 
applications, and finding ways 
to sustain such treatments in 
areas where LGBTQ stigma is 
present and strong.
“David’s journey inspires 
all of us to be as courageous 
and creative as his generation 
has been in living proudly and 
meaningfully in the face of 
societal and emotional barri-
ers,” said Pachankis. “For a lot 
of LGBTQ people, that journey 
includes supporting the next 
generation of LGBTQ individuals. 
at’s certainly one of David’s 
major contributions and, in my 
own way as a researcher and 
teacher, I hope that it can be one 
of mine.”
After coming out in San 
Francisco, Kessler helped launch 
the country’s first formal gay 
doctors’ organization, Bay Area 
Physicians for Human Rights. He 
later served as president of the 
National Gay Caucus of Members 
of the American Psychiatric 
Association, which became the 
American Association of Gay and 
Lesbian Psychiatrists. People 
magazine highlighted his leader-
ship and advocacy work in 1979. 
He gave one of the eulogies at the 
funeral of Harvey Milk, a key fig-
ure in the gay rights movement.
Kessler credits his friends 
in the gay community with 
providing the crucial support 
he needed to acknowledge his 
sexual orientation—and main-
tain his sanity—at a time when 






















Jeorg Bewersdorf didn’t 
start out looking to 
become one of the fore-
most global experts in 
creating bespoke micro-
scopes. A serendipitous 
class with future Nobel 
Prize winner Stefan Hell 
set Bewersdorf on his 
path to success.




public.  e early groups would 
meet after dark in the shel-
ter of members’ living rooms. 
 ere, discussion would drag 
on for hours about how mem-
bers would be kept informed, 
whether there should be a 
printed membership list, who 
should possess the list, and 
what might happen if it fell 
into the wrong hands. Even 
the group’s initial chosen 
name—Bay Area Physicians for 
Human Rights—made no men-
tion of homosexuality.
After completing his psychi-
atric residency at Yale in 1961, 
Kessler went on to become a fac-
ulty member in the Department 
of Psychiatry at the University of 
California San Francisco Medical 
School and also a unit supervisor 
at the Langley Porter Institute. 
He retired as a clinical professor 
of psychiatry in 1986, just as 
his efforts were beginning to 
bear fruit.
 e Lesbian and Gay Studies 
Center at Yale, established in 
1986, was one of the fi rst of 
its kind in the country.  e 
Research Fund for Lesbian and 
Gay Studies (FLAGS), established 
in 1992, supports faculty and 
graduate student research, and 
the university is widely known 
for its national conferences. 
In 2001, Arthur Kramer ’49, 
made a major donation in honor 
of his brother, the writer, AIDS 
activist, and ACT UP founder 
Larry Kramer ’57.  at led to 
the establishment of the Larry 
Kramer Initiative for Lesbian 
and Gay Studies. LKI, as it was 
known, was a highly successful 
fi ve-year initiative to appoint 
visiting lecturers and dramati-
cally expand Yale’s archive of 
LGBTQ materials, including 
the papers of Kramer and fel-
low activists David Mixner and 
Harvey Fierstein.
Kessler said he has been 
interested in creating something 
at Yale for years, but it took two 
tries to get it done.  e fi rst time 
he approached the university, in 
the early 1990s, the people he 
met with weren’t sure where the 
funds should be directed or how 
they might be used, and Kessler 
chose instead to create the David 
R. Kessler Lectures in Lesbian 
and Gay Studies at his other 
alma mater, the City University 
of New York.
A longtime supporter of 
Yale School of Medicine (YSM), 
Kessler decided to make an 
estate gift to Yale School of 
Public Health after speaking 
with Vermund and YSM Deputy 
Dean and Chief Diversity 
Offi  cer Darin Latimore, 
MD, who introduced him to 
Pachankis last year. Kessler 
hopes his endowment encour-
ages others to support YSPH’s 
ongoing efforts to improve 
mental health outcomes for the 
LGBTQ community.
“Now Yale is ready, willing, 
and able, with a research pro-
gram in full swing that is very 
close to my heart,” Kessler said. 
“I am delighted to be able to 




Taking aim at sickle 
cell disease —an unfairly 
neglected malady
Global Blood  erapeutics (GBT) 
is a promising up-and-coming 
biotechnology company in South 
San Francisco. It is currently 
focused on bringing voxelotor, a 
potential treatment for sickle cell 
disease (SCD), to the public—the 
drug may be submitted for FDA 
approval this year. If successful, 
GBT stands to revolutionize health 
in a traditionally marginalized 
and overlooked community. Ted 
W. Love, MD ’85, is its president 
and chief executive offi  cer.
If you think there’s a lot of 
stress on Love’s shoulders, you 
wouldn’t know it to talk with 
him. “It’s a real honor, to be able 
to work with all the talented 
people here,” said Love. “ at’s 
one of the perks of success: better 
access to bigger challenges, and 
the type of professionals who like 
to take on those challenges.”
Even during his childhood in 
Alabama, Love was powerfully 
attracted to a career in medicine, 
though in interviews he’s also 
expressed admiration for mili-
tary pilots.  e combination of 
excitement, potential to change 
the world for the better, and 
opportunity for ethical leader-
ship appealed to him. Perhaps 
it isn’t terribly surprising, then, 
that Love’s interest in medicine 
led him to combine his passion 
for science with the excitement 
of entrepreneurialism.
His professional experi-
ences prepared Love well for his 
responsibilities at GBT. Once 
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she told him left an indelible 
mark on him as a young leader.
“She listened to me describe 
the situation, patiently. And when 
I was done, she said: ‘When the 
going gets tough, the tough get 
going.’ It was a long medical rota-
tion, but I understood what she 
meant: being a doctor is a respon-
sibility. You promise to help peo-
ple, that’s what you do. It’s on you. 
I’ve never forgotten that lesson.”
Mentors like Bia, professor 
emeritus of medicine (nephrol-
ogy), who retired in 2018 after 
40 years of service, are just part of 
the reason Love remembers Yale 
School of Medicine fondly. He 
described relationships with other 
students that have stood the test 
of time, and opportunities that 
the school opened up for him.
“e School of Medicine 
played a big role in who I am 
today,” said Love. “Ultimately, 
I’m very grateful.”
—Adrian Bonenberger
he completed his residency 
and fellowship training in 
internal medicine and cardiol-
ogy at Harvard Medical School 
(via Massachusetts General 
Hospital), he went on to serve 
in leadership roles at various 
companies and committees, 
including Genentech, eravance 
Biopharma, Nuvelo, Onyx 
Pharmaceuticals, and California’s 
Independent Citizens’ Oversight 
Committee for stem-cell 
research, among others.
After his last job, Love could 
have easily retired to enjoy his 
wine collection in Sonoma, 
Calif., but GBT coaxed him back 
into action. e reason for his 
return was a lingering sense that 
he could do more for the African 
American community, which 
suffers disproportionately from 
SCD. Sickle cell was not viewed 
as an “urgent” disease like some 
other diseases that affect spe-
cific groups—evidence, perhaps, 
of systemic bias—and GBT’s 
voxelotor offered a rare possibil-
ity to create a viable treatment 
in spite of the lack of traditional 
market incentives. Voxelotor, 
which is taken by mouth once 
daily, prevents red blood cells 
from becoming sickle-shaped 
and breaking down by increas-
ing their affinity for oxygen and 
restoring normal hemoglobin 
function. e premature break-
down of red blood cells in people 
with SCD causes serious long-
term consequences, including 
anemia, organ damage, stroke, 
and a shortened life span. “I 
wanted to make a difference, 
where in the past I didn’t have 
the power to help,” said Love.
With a résumé like Love’s, 
it’s hard to pick out specific 
moments on which to focus. 
Marriage and fatherhood (Love 
is married with three daughters 
and three granddaughters) have 
been sources of positivity and 
pride in his life, as has his edu-
cational path. Asked about his 
memories of New Haven, Love 
says that he learned important 
lessons about what it meant to be 
a doctor and practice medicine 
while at Yale. He emphasized one 
experience in particular.
“One day I was doing rounds, 
and Margaret ‘Peggy’ Bia, MD, 
FW ’78, was my attending,” said 
Love. “It was a night shift, and 
slow, and like most students I 
was perhaps slightly overconfi-
dent in my abilities … I let more 
patients in than usual, because I 
knew I could handle it.”
Love said that the next thing 
he knew, unexpected patients 
flooded in, overwhelming him. 
“I called Dr. Bia, asking for help, 
hoping she could help me reduce 




























The training and 
mentorship Ted Love re-
ceived at Yale School of 
Medicine from teachers 
like Margaret “Peggy” 
Bia helped prepare him 
for the rigors of the 
business world. Now, 
the company of which 
he’s CEO has a chance 
to bring an e¤ective 






Group, which designs, 
plans, and executes 
multicenter studies that 
test medical devices in 
clinical trials.
Within these roles, 
Lansky started one 
of the earliest clini-
cal research programs 
to offer transcatheter 
aortic valve implanta-
tion (TAVI also known 
as transcatheter aortic 
valve replacement, or 
TAVR). Performed in 
patients with a nar-
rowed aortic valve, this 
procedure allows car-
diologists to thread a 
catheter through a blood 
vessel in the leg up to the 
heart to implant a new 
aortic valve—thus avoid-
ing open-heart surgery. 
While cardiac 
interventional tech-
nologies have drastically 
improved over the past 
two decades, a stubborn 
risk remains: strokes. 
During any cardiac 
procedures, plaque or 
calcium buildup can 
break off in small pieces, 
float up into the brain, 
and block a narrow 
blood vessel there, caus-
ing a stroke. A highly 
specialized tool called 
an embolic protection 
device is currently used 
during TAVI to prevent 
some of the released 
debris from reaching 
the brain. However, the 
devices are not foolproof. 
After years of experience, 
Lansky decided she 
could do better.
Why did you see a 
need to invent another 
embolic protection 
device? During TAVI, 
when the new valve 
replaces the old valve, 
some debris can come 
loose. Stroke rates hover 
around 3% in patients 
who have this procedure. 
Stroke risk is lower with 
TAVI than with surgery. 
However, our studies with 
brain imaging show that 
virtually all patients have 
some degree of neurologic 
injury—they just may not 
show any symptoms. None 
of the current deflection 
technologies fully seals off 
the cerebral vessels. The 
device our team invented 
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question and answer
ALL CARDIAC PROCEDURES carry a risk of stroke because plaque 
or calcium buildup can break off in small pieces, float up into the 
brain, and block narrow blood vessels. A highly specialized tool 
called an embolic protection device is currently used to prevent 
some of the released debris from reaching the brain.
{ To nominate a subject for Q&A, contactYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu.
When Alexandra 
Lansky, MD, professor 
of medicine, finished 
her first fellowship 
in 1996, patients who 
needed swift interven-
tion to clear plaque that 
threatened to block 
blood vessels supply-
ing their hearts had 
limited options. Doctors 
used a catheter with 
an inflatable balloon 
to squeeze the plaque 
buildup against the 
vessel wall. Later came 
metallic stents that 
could be inserted over 
the plaque to widen 
the vessel. Open-heart 
surgery was the only 
option for correcting 
valve-related problems. 
“Interventional cardiol-
ogy was in its infancy,” 
Lansky said. e British-
born, French-raised car-
diologist felt drawn to 
the field by the oppor-
tunity to refine devices 
that could save lives 
and even permanently 
address heart disease.
Since she arrived 
at Yale eight years 
ago, Lansky has built 
a vast infrastructure of 
clinical studies—with 
countless moving parts, 
such as active patient 
recruitment, compli-
ance, and research 
approval—within the 
section of cardiovascular 
medicine at Yale School 
of Medicine. Nearly 
100 clinical trials  
are ongoing under her 
leadership as direc-
tor of the Yale Heart 
and Vascular Clinical 
Research Program. She 






addresses this weak spot. 
It completely seals off 
blood flow to the brain 
using a mesh netting with 
pore sizes of less than 
120 microns. We are in 
the early phases of devel-
opment and hope to be 
able to bring this to our 
patients soon.
What else is your clinical 
research program look-
ing at with TAVI? Our 
Yale research program has 
established a partner-
ship with the Barts Heart 
Centre and Queen Mary 
University of London 
focused on cardiovascular-
device innovation and 
evaluation. Minimally 
invasive and device-based 
approaches to ischemic and 
structural heart disease 
have taken center stage 
in our field. Procedures 
like TAVI are proving to be 
safe and effective, as well 
as reducing hospital-stay 
times. This has added up 
to lower health care costs, 
better outcomes, and hap-
pier patients. This has 
been a major initiative 
of the United Kingdom’s 
National Health Service and 
is increasingly important 
in the United States as we 
try to contain health care 
costs. We’ve found that 
TAVI patients in the hospi-
tal stay two to three days 
interventional treatment 
and how to evaluate them 
in less invasive ways. For 
coronary artery disease, the 
angiogram has been the 
gold standard. A wire-based 
assessment of the coronary 
blockage currently allows 
us to measure the pressure 
drop from before and after 
the blockage. If the pres-
sure drop is below 80% of 
normal flow, then treatment 
with a stent is justified. This 
approach, though benefi-
cial, is invasive and requires 
threading a wire through 
the blood vessel. Right now 
we are testing and validat-
ing a method that relies on 
the images produced by an 
angiogram to determine 
pressure changes. Using 
computational modeling 
based on the X-ray images, 
we can reliably simulate the 
pressure drop without hav-
ing to rely on a wire or cre-
ate potential complications 
and patient discomfort. This 
is expanding the diagnostic 
value of the angiogram and 
allows us to more broadly 
find out which patients 
should be treated. We are 
also working on integrating 
artificial intelligence into 
diagnostics and on better 
patient selection 
for treatment. I predict we 
will have much more to 
report on this area in the 
near future.
compared to five to seven 
days following open-heart 
surgery. In general, TAVI 
patients do not need to go 
to a skilled nursing facility 
for recuperation. They just 
go home. It has completely 
changed the equation in 
terms of recovery and 
health care costs. 
TAVI sounds like a revolu-
tionary procedure in  
cardiology. TAVI has 
been a revolution for our 
patients, who generally 
want to avoid a visit to the 
surgical operating room 
if at all possible. After 15 
years of rigorous clinical 
testing of patients with 
aortic stenosis, it has com-
pletely changed how these 
patients are being treated. 
At this year’s American 
College of Cardiology 
(ACC) annual meeting, we 
heard Eugene Braunwald, 
MD, considered to be the 
father of modern cardiol-
ogy, comment on the latest 
results of the use of TAVI 
in younger and low-risk 
patients with aortic ste-
nosis. He said, “This is a 
historic moment. We will 
be telling our children and 
grandchildren about these 
remarkable results.”
What will be the next 
medical innovation in 
heart disease? We are 
finding better ways to iden-


















The narrow gap between 
animal and human viruses
By Cathy Shufro
When a pet prairie dog bit a 
3-year-old in Wisconsin in 
2003, the child contracted an 
infection endemic to central 
and western Africa. How had 
the monkeypox virus reached 
the American Midwest? 
is is the kind of puzzle
that Warren A. Andiman, MD, 
FW ’76, explores in Animal 
Viruses and Humans: A 
Narrow Divide. e book 
teaches readers about mecha-
nisms that allow zoonotic 
viruses to move from animals 
to humans and gives detailed 
accounts of viral outbreaks, 
including the severe acute 
respiratory syndrome (SARS), 
rabies, and Ebola. Andiman, 
professor emeritus of pediat-
rics and public health at Yale, 
also addresses the political, 
economic, and environmental 
forces that are escalating the 
threat of zoonoses worldwide. 
In the case of the 
Wisconsin girl bitten by 
her pet, it turns out that an 
exotic-pet dealer in Illinois 
had housed prairie dogs with 
rodents imported from Africa, 
including a Gambian rat car-
rying monkeypox. Several 
other Midwesterners got sick, 
but nobody died, and no 
monkeypox has since been 
reported in the United States. 
e prairie dog story 
illustrates Andiman’s under-
standing of why viruses 
threaten us. Because they 
mutate “promiscuously,” he 
explains, “viruses, unlike 
most living organisms, have 
found ways to populate every 
nook and cranny of the 
entire planet.” Global travel, 
climate change, and refugees 
on the move have increased 
contact between animals and 
crowds of humans. Animal 
groups that carry five or 
more viruses that can infect 
us include birds, bats, pigs, 
primates, and rodents. To 
those carriers, add insects. 
“Imagine throwing billions 
of biting insects into the 
already swirling cauldron 
of animals and humans …” 
Andiman remarked.
When SARS appeared in 
southern China and began 
spreading in 2003, research-
ers around the world rallied 
to work on vaccines and 
antivirals, but the epidemic 
ended without the help of 
either. e same thing hap-
pened during the 2014-2015 
Ebola outbreak in West Africa. 
erefore, drug development 
doesn’t appear in Andiman’s 
“holy trinity” of zoonotic 
disease control; it requires 
too much time and money. 
Instead, local and national 
engagement come first in 
stemming transmission, 
including locating patients 
and tracing contacts; isolating 
the sick; minimizing stigma; 
alerting global health officials 
the minute an outbreak is 
discovered; and accepting 
outside help. Second, avoiding 
epidemics requires perpetual 
surveillance, perhaps even 
testing people working with 
pigs, such as the half-million 
Americans employed by the 
pork industry. 
e third constituent 
of the trinity is foreign aid: 
building treatment cen-
ters, improving roads, and 
providing protective cloth-
ing for health workers and 
cold chains for medications. 
Foreign aid can support 
what Andiman described in 
an interview as “very basic 
public health practices we’ve 
known about for a hundred 
years: clean water, clean food, 
clean hands. When you give 
aid, you are helping your-
self and your countrymen, 
because these viruses are bor-
derless agents. ere are no 
real borders anymore.”
Andiman knows some-
thing about borderless viruses. 
He and nurse practitioner 
Leetha Fraulino established 
the first AIDS program in New 
Haven in 1982, at a time when 
health care workers risked 
their own lives. “We didn’t 
even know it was a virus, and 
we knew nothing about the 
way it was transmitted. I was 
very worried.” He directed the 
Pediatric AIDS Care Program 
at Yale New Haven Hospital for 
32 years. When the program 
began, one in five mothers 
with HIV passed the virus 
on to their babies. By 1996, 
policies governing testing and 
patient care had brought the 
transmission rate to zero. 
Andiman imagined an 
audience of educated but non-
expert readers during the 
two years he spent writing 
Animal Viruses and Humans. 
His aim was to explain how 
the control of zoonotic dis-
eases can benefit all of us in 

























{Send notices of new books toYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu.
book review
A F T E R A T H R E E-Y E A R H I AT US, an annual Yale School of Medicine tradition made its triumphant 
return to the stage on Saturday, March 30, to very positive reviews.
Written, directed, and performed by graduating medical students and MD-PhD candidates, ­e 
Final Master Course was a musical sendup of the Class of 2019’s medical-school experience. Many of 
the parts were filled by enthusiastic students whose energy more than made up for their inexperi-
ence on stage, though some clearly had backgrounds in music and theater. 
Formerly known as the “Second-Year Show” and held by second-year medical students, the 
reborn Fourth-Year Show gave students a chance to poke lighthearted fun at themselves, one 
another, beloved faculty, and administrators. 
“We very much hope that this show will cement the newly revived tradition of the Fourth-Year 
Show for years to come,” said Jack Zhao, fourth-year student and executive producer.
—Adrian Bonenberger
Fourth-year show 
returns with a blast
49Summer 2019
end note
